GE HealthCare (GEHC) 10-Q30 Oct 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2024	Oct. 23, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-41528
Entity Registrant Name	GE HEALTHCARE TECHNOLOGIES INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2515116
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60661
City Area Code	833
Local Phone Number	735-1139
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	GEHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		456,872,979
Amendment Flag	false
Entity Central Index Key	0001932393
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total revenues	$ 4,863	$ 4,822	$ 14,353	$ 14,346
Gross profit	2,026	1,935	5,930	5,766
Selling, general, and administrative	1,034	996	3,139	3,130
Research and development	316	322	967	890
Total operating expenses	1,350	1,318	4,106	4,020
Operating income	676	617	1,824	1,746
Interest and other financial charges – net	130	138	383	411
Non-operating benefit (income) costs	(102)	(94)	(306)	(332)
Other (income) expense – net	(9)	(63)	(1)	(85)
Income from continuing operations before income taxes	658	636	1,747	1,752
Benefit (provision) for income taxes	(168)	(250)	(435)	(550)
Net income from continuing operations	490	386	1,312	1,202
Income (loss) from discontinued operations, net of taxes	0	(4)	0	(4)
Net income	490	382	1,312	1,198
Net (income) loss attributable to noncontrolling interests	(19)	(7)	(40)	(33)
Net income attributable to GE HealthCare	470	375	1,272	1,165
Deemed preferred stock dividend of redeemable noncontrolling interest	0	0	0	(183)
Net income attributable to GE HealthCare common stockholders	$ 470	$ 375	$ 1,272	$ 982
Earnings per share from continuing operations attributable to GE HealthCare common stockholders:
Basic (in dollars per share)	$ 1.03	$ 0.83	$ 2.79	$ 2.17
Diluted (in dollars per share)	1.02	0.83	2.77	2.16
Earnings per share attributable to GE HealthCare common stockholders:
Basic (in dollars per share)	1.03	0.82	2.79	2.16
Diluted (in dollars per share)	$ 1.02	$ 0.82	$ 2.77	$ 2.15
Weighted-average number of shares outstanding:
Basic (in shares)	457	455	456	455
Diluted (in shares)	459	458	459	458
Product
Total revenues	$ 3,201	$ 3,186	$ 9,454	$ 9,530
Cost of revenue	2,033	2,076	6,045	6,197
Service
Total revenues	1,662	1,636	4,899	4,816
Cost of revenue	$ 805	$ 811	$ 2,378	$ 2,383

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income attributable to GE HealthCare	$ 470	$ 375	$ 1,272	$ 1,165
Net (income) loss attributable to noncontrolling interests	19	7	40	33
Net income	490	382	1,312	1,198
Other comprehensive income (loss):
Currency translation adjustments – net of taxes	177	(143)	70	(84)
Pension and Other Postretirement Plans – net of taxes	(67)	(264)	(138)	(346)
Cash flow hedges – net of taxes	(36)	22	(12)	(7)
Other comprehensive income (loss)	74	(385)	(80)	(437)
Comprehensive income (loss)	563	(3)	1,232	761
Less: Comprehensive income (loss) attributable to noncontrolling interests	19	(28)	40	(2)
Comprehensive income attributable to GE HealthCare	$ 544	$ 25	$ 1,192	$ 763

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Cash, cash equivalents, and restricted cash	$ 3,568	$ 2,504
Inventories	2,124	1,960
Contract and other deferred assets	1,046	1,000
All other current assets	476	389
Current assets	10,638	9,410
Property, plant, and equipment – net	2,539	2,500
Goodwill	13,138	12,936
Other intangible assets – net	1,132	1,253
Deferred income taxes	4,309	4,474
All other non-current assets	2,098	1,881
Total assets	33,855	32,454
Short-term borrowings	1,007	1,006
Accounts payable	2,911	2,947
Contract liabilities	1,915	1,918
Current compensation and benefits	1,422	1,518
Current liabilities	8,670	8,981
Long-term borrowings	9,306	8,436
Non-current compensation and benefits	5,388	5,782
Deferred income taxes	59	68
All other non-current liabilities	1,920	1,877
Total liabilities	25,343	25,144
Commitments and contingencies
Redeemable noncontrolling interests	177	165
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 457,144,443 shares issued as of September 30, 2024; 455,342,290 shares issued as of December 31, 2023	5	5
Treasury stock, at cost, 291,053 shares as of September 30, 2024 and 0 shares as of December 31, 2023	(25)	0
Additional paid-in capital	6,551	6,493
Retained earnings	2,558	1,326
Accumulated other comprehensive income (loss) – net	(771)	(691)
Total equity attributable to GE HealthCare	8,317	7,133
Noncontrolling interests	18	12
Total equity	8,335	7,145
Total liabilities, redeemable noncontrolling interests, and equity	33,855	32,454
Nonrelated party
Receivables, net	3,418	3,525
All other current liabilities	1,409	1,493
Related party
Receivables, net	6	32
All other non-current assets	70	81
All other current liabilities	7	99
All other non-current liabilities	$ 41	$ 33

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Financial Position (Unaudited) (Parentheticals) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 104	$ 98
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	457,144,443	455,342,290
Treasury stock (in shares)	291,053	0

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Millions	Total	Common stock	Treasury stock	Additional paid-in capital	Retained earnings	Net parent investment	Accumulated other comprehensive income (loss) – net	Equity attributable to noncontrolling interests
Equity, beginning balance (in shares) at Dec. 31, 2022		0
Equity, beginning balance at Dec. 31, 2022	$ 9,362	$ 0		$ 0	$ 0	$ 11,235	$ (1,878)	$ 5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net transfers from GE, including Spin-Off-related adjustments	(2,840)					(4,842)	2,000	2
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment (in shares)		454,000,000
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	0	$ 5		6,388		(6,393)
Issuance of shares under equity awards, net of shares withheld for taxes and other (in shares)		1,000,000
Net income attributable to GE HealthCare	1,165				1,165
Dividends declared	(41)				(41)
Other comprehensive income (loss) attributable to GE HealthCare	(402)						(402)
Changes in equity attributable to noncontrolling interests	4							4
Share-based compensation	81			81
Changes in equity due to redemption value adjustments on redeemable noncontrolling interests	(187)				(187)
Equity, ending balance (in shares) at Sep. 30, 2023		455,000,000
Equity, ending balance at Sep. 30, 2023	7,142	$ 5		6,469	937	0	(280)	11
Equity, beginning balance (in shares) at Jun. 30, 2023		455,000,000
Equity, beginning balance at Jun. 30, 2023	7,114	$ 5		6,451	576	0	70	12
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under equity awards, net of shares withheld for taxes and other	(11)			(11)
Net income attributable to GE HealthCare	375				375
Dividends declared	(14)				(14)
Other comprehensive income (loss) attributable to GE HealthCare	(350)						(350)
Changes in equity attributable to noncontrolling interests	(1)							(1)
Share-based compensation	29			29
Equity, ending balance (in shares) at Sep. 30, 2023		455,000,000
Equity, ending balance at Sep. 30, 2023	$ 7,142	$ 5		6,469	937	$ 0	(280)	11
Equity, beginning balance (in shares) at Dec. 31, 2023	455,342,290	455,000,000
Equity, beginning balance at Dec. 31, 2023	$ 7,145	$ 5	$ 0	6,493	1,326		(691)	12
Treasury stock, beginning balance (in shares) at Dec. 31, 2023	0		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under equity awards, net of shares withheld for taxes and other (in shares)		2,000,000
Issuance of shares under equity awards, net of shares withheld for taxes and other	$ (59)		$ (25)	(34)
Net income attributable to GE HealthCare	1,272				1,272
Dividends declared	(41)				(41)
Other comprehensive income (loss) attributable to GE HealthCare	(80)						(80)
Changes in equity attributable to noncontrolling interests	6							6
Share-based compensation	$ 92			92
Equity, ending balance (in shares) at Sep. 30, 2024	457,144,443	457,000,000
Equity, ending balance at Sep. 30, 2024	$ 8,335	$ 5	$ (25)	6,551	2,558		(771)	18
Treasury stock, ending balance (in shares) at Sep. 30, 2024	(291,053)		0
Equity, beginning balance (in shares) at Jun. 30, 2024		457,000,000
Equity, beginning balance at Jun. 30, 2024	$ 7,817	$ 5	$ 0	6,540	2,101		(845)	16
Treasury stock, beginning balance (in shares) at Jun. 30, 2024			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under equity awards, net of shares withheld for taxes and other	(35)		$ (25)	(10)
Net income attributable to GE HealthCare	470				470
Dividends declared	(14)				(14)
Other comprehensive income (loss) attributable to GE HealthCare	74						74
Changes in equity attributable to noncontrolling interests	2							2
Share-based compensation	$ 21			21
Equity, ending balance (in shares) at Sep. 30, 2024	457,144,443	457,000,000
Equity, ending balance at Sep. 30, 2024	$ 8,335	$ 5	$ (25)	$ 6,551	$ 2,558		$ (771)	$ 18
Treasury stock, ending balance (in shares) at Sep. 30, 2024	(291,053)		0

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]
Dividends declared per common share (in dollars per share)	$ 0.03	$ 0.03	$ 0.09	$ 0.09

Condensed Consolidated Statem_7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows - operating activities
Net income	$ 1,312	$ 1,198
Less: Income (loss) from discontinued operations, net of taxes	0	(4)
Net income from continuing operations	1,312	1,202
Adjustments to reconcile Net income from continuing operations to Cash from (used for) operating activities
Depreciation of property, plant, and equipment	203	188
Amortization of intangible assets	237	278
Gain on fair value remeasurement of contingent consideration	(19)	(17)
Net periodic postretirement benefit plan (income) expense	(271)	(291)
Postretirement plan contributions	(257)	(259)
Share-based compensation	92	81
Provision for income taxes	435	550
Cash paid during the year for income taxes	(375)	(375)
Changes in operating assets and liabilities, excluding the effects of acquisitions:
Receivables	83	(82)
Due from related parties	24	9
Inventories	(157)	(85)
Contract and other deferred assets	(33)	(75)
Accounts payable	3	(93)
Due to related parties	(72)	(87)
Contract liabilities	(25)	69
Current compensation and benefits	(97)	37
All other operating activities - net	(41)	1
Cash from (used for) operating activities – continuing operations	1,042	1,051
Cash flows – investing activities
Additions to property, plant and equipment and internal-use software	(299)	(293)
Dispositions of property, plant, and equipment	0	1
Purchases of businesses, net of cash acquired	(259)	(147)
Purchases of investments	(33)	(21)
All other investing activities - net	(83)	(10)
Cash from (used for) investing activities – continuing operations	(674)	(470)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	0	(9)
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	994	2,020
Repayments and other reductions (maturities longer than 90 days)	(162)	(9)
Dividends paid to stockholders	(41)	(28)
Redemption of noncontrolling interests	0	(211)
Net transfers (to) from GE	0	(1,317)
Proceeds from stock issued under employee benefit plans	31	31
Taxes paid related to net share settlement of equity awards	(90)	(31)
All other financing activities - net	(28)	(24)
Cash from (used for) financing activities – continuing operations	704	422
Cash from (used for) operating activities – discontinued operations	(4)	0
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	(2)	(34)
Increase (decrease) in cash, cash equivalents, and restricted cash	1,066	969
Cash, cash equivalents, and restricted cash at beginning of year	2,506	1,451
Cash, cash equivalents, and restricted cash as of September 30	3,572	2,420
Supplemental disclosure of cash flows information
Cash paid during the year for interest	(339)	(318)
Non-cash investing activities
Acquired but unpaid property, plant, and equipment	$ 72	$ 80

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	9 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. We operate at the center of the healthcare ecosystem, helping enable precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater efficiency, access, and personalized medicine. Our products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from diagnosis to therapy to monitoring. On January 3, 2023, the General Electric Company, which now operates as GE Aerospace (“GE”), completed the spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”). The Spin-Off was completed through a distribution of approximately 80.1% of the Company’s outstanding common stock to holders of record of GE’s common stock as of the close of business on December 16, 2022 (the “Distribution”), which resulted in the issuance of approximately 454 million shares of common stock. Prior to the Distribution, the Company issued 100 shares of common stock in exchange for $1.00, all of which were held by GE as of December 31, 2022. As a result of the Distribution, the Company became an independent public company. On April 2, 2024, GE completed the separation of its GE Vernova business into an independent publicly traded company. As of September 30, 2024, GE’s beneficial ownership was approximately 2.9% of the Company’s outstanding common stock. In connection with the Spin-Off, certain adjustments were recorded to reflect transfers from GE, the draw-down of the Term Loan Facility, and settlement of Spin-Off transactions with GE, which resulted in the net reduction in Total equity of $2,840 million. These items substantially consisted of the transfer of: (1) certain pension plan liabilities and assets, (2) certain deferred income taxes, (3) deferred compensation liabilities, and (4) employee termination obligations. In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE. See Note 17, “Related Parties and Transition Services Agreement” for more information on these agreements and related transactions. The condensed consolidated financial statements (the “financial statements”) have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the financial statements. Operating results for the three and nine months ended September 30, 2024 and 2023 are not necessarily indicative of the results that may be expected for the fiscal year as a whole. The December 31, 2023 period presented on the Condensed Consolidated Statement of Financial Position was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts. Certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year presentation, which provides additional detail to readers of the financial statements. Amounts related to current compensation and benefit obligations that were previously reported within the All other current liabilities and All other operating activities lines on the Condensed Consolidated Statements of Financial Position and Statements of Cash Flows, respectively, have been reclassified to separate lines on the respective financial statements. Additionally on the Condensed Consolidated Statements of Cash Flows, amounts related to purchase of investments previously reported within All other investing activities, and amounts related to equity award activity previously reported within All other financing activities, have been reclassified to separate lines. Effective July 1, 2024, Image Guided Therapies (“IGT”), previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting. The Ultrasound segment was subsequently renamed Advanced Visualization Solutions (“AVS”). Following this realignment, the Company continues to have four reportable segments: Imaging, AVS, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. Historical segment financial information presented within this report has been recast to conform to the new reportable segments structure. See Note 3, “Segment Information” for more information. The financial statements and notes should be read in conjunction with the Company’s audited consolidated and combined financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. ESTIMATES AND ASSUMPTIONS. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. RECENT ACCOUNTING PRONOUNCEMENTS. In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect that ASU 2023-07 will have on our financial statement disclosures. In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures . ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect that ASU 2023-09 will have on our financial statement disclosures.

REVENUE RECOGNITION

REVENUE RECOGNITION	9 Months Ended
REVENUE RECOGNITION	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as on-demand service parts, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services. CONTRACT ASSETS. Contract assets reflect revenue recognized on contracts with customers in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs. Contract and Other Deferred Assets As of September 30, 2024 December 31, 2023 Contract assets $ 685 $ 600 Other deferred assets 361 400 Contract and other deferred assets 1,046 1,000 Non-current contract assets (1) 93 72 Non-current other deferred assets (1) 96 96 Total contract and other deferred assets $ 1,235 $ 1,168 (1) Non-current contract and other deferred assets are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. CONTRACT LIABILITIES. Contract liabilities include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which remaining performance obligations (“RPO”) are expected to be satisfied with our customers. As of September 30, 2024 and December 31, 2023, contract liabilities were approximately $2,619 million and $2,623 million, respectively, of which the non-current portion of $704 million and $705 million, respectively, was recognized in All other non-current liabilities in the Condensed Consolidated Statements of Financial Position. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $1,381 million and $1,357 million for the nine months ended September 30, 2024 and 2023, respectively. REMAINING PERFORMANCE OBLIGATIONS. RPO represents the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the right to cancel or terminate without incurring a substantive penalty. As of September 30, 2024, the aggregate amount of the contracted revenues allocated to our unsatisfied performance obligations was $14,563 million. We expect to recognize revenue as we satisfy our RPO as follows: (1) product-related RPO of $4,808 million of which 98% is expected to be recognized within two years, and the remaining thereafter; and (2) services-related RPO of $9,756 million of which 64% and 91% are expected to be recognized within two years and five years, respectively, and the remaining thereafter.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
SEGMENT INFORMATION	Sep. 30, 2024
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Effective July 1, 2024, Image Guided Therapies, previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting. The Ultrasound segment was subsequently renamed Advanced Visualization Solutions. The AVS segment has a portfolio that serves customers across two core areas: Specialized Ultrasound and Procedural Guidance. Specialized Ultrasound includes Radiology, Primary Care and Point of Care, and Women’s Health Ultrasound. Procedural Guidance includes Cardiovascular and Interventional Solutions, and Surgical Innovations. Under the new structure, IGT is reported within the Procedural Guidance business in AVS. Historical segment financial information presented within this report has been recast to conform to the new reportable segments structure. Following this realignment, the Company continues to have four reportable segments: Imaging, AVS, PCS, and PDx. These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. The performance of these segments was principally measured based on Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gain (loss). Total Revenues by Segment For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Total Imaging $ 2,229 $ 2,236 $ 6,462 $ 6,552 AVS: Procedural Guidance 647 641 1,967 1,938 Specialized Ultrasound 569 573 1,725 1,774 Total AVS 1,216 1,214 3,692 3,712 PCS: Monitoring Solutions 556 573 1,621 1,688 Life Support Solutions 223 191 677 627 Total PCS 779 764 2,298 2,315 Total PDx 625 589 1,862 1,715 Other (1) 15 19 39 52 Total revenues $ 4,863 $ 4,822 $ 14,353 $ 14,346 (1) Financial information not presented within the reportable segments, shown within the Other category, represents Hea lthCar e Financial Services (“HFS”) which does not meet the definition of an operating segment. Segment EBIT For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Segment EBIT Imaging $ 287 $ 243 $ 660 $ 566 AVS 232 254 744 798 PCS 82 80 241 273 PDx 193 166 571 473 Other (1) 1 1 2 9 795 744 2,217 2,119 Restructuring costs (22) (3) (90) (34) Acquisition and disposition-related benefits (charges) 4 14 7 15 Gain (loss) on business and asset dispositions (1) — — — Spin-Off and separation costs (56) (45) (182) (175) Amortization of acquisition-related intangible assets (34) (32) (100) (95) Investment revaluation gain (loss) (1) 2 (26) 1 Interest and other financial charges – net (130) (138) (383) (411) Non-operating benefit income (costs) 102 94 306 332 Income before income taxes $ 658 $ 636 $ 1,747 $ 1,752 (1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS which does not meet the definition of an operating segment.

RECEIVABLES

RECEIVABLES	9 Months Ended
RECEIVABLES	Sep. 30, 2024
Receivables [Abstract]
RECEIVABLES	RECEIVABLES Current Receivables As of September 30, 2024 December 31, 2023 Current customer receivables (1) $ 3,265 $ 3,339 Non-income based tax receivables 139 166 Other sundry receivables 119 118 Current sundry receivables 257 284 Allowance for credit losses (104) (98) Total current receivables – net $ 3,418 $ 3,525 (1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $135 million and $144 million as of September 30, 2024 and December 31, 2023, respectively. Long-Term Receivables As of September 30, 2024 December 31, 2023 Long-term customer receivables $ 72 $ 55 Non-income based tax receivables 23 26 Other sundry receivables 102 73 Long-term sundry receivables 125 99 Allowance for credit losses (30) (30) Total long-term receivables – net (1) $ 167 $ 124 (1) Long-term receivables are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

FINANCING RECEIVABLES

FINANCING RECEIVABLES	9 Months Ended
FINANCING RECEIVABLES	Sep. 30, 2024
Receivables [Abstract]
FINANCING RECEIVABLES	FINANCING RECEIVABLES As of September 30, 2024 December 31, 2023 Loans receivable, at amortized cost $ 23 $ 29 Investment in financing leases, net of deferred income 74 71 Allowance for credit losses (3) (3) Current financing receivables – net (1) 94 97 Loans receivable, at amortized cost 32 37 Investment in financing leases, net of deferred income 151 146 Allowance for credit losses (5) (5) Non-current financing receivables – net (1) $ 178 $ 178 (1) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Condensed Consolidated Statements of Financial Position. As of September 30, 2024 , 4%, 4%, and 4% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2023 , 5%, 5%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

LEASES

LEASES	9 Months Ended
LEASES	Sep. 30, 2024
Leases [Abstract]
LEASES	LEASES Operating lease liabilities recognized within All other current liabilities and All other non-current liabilities in the Condensed Consolidated Statements of Financial Position were $378 million and $383 million as of September 30, 2024 and December 31, 2023, respectively. The total lease expense related to our operating lease portfolio was $70 million and $54 million for the three months ended September 30, 2024 and 2023, respectively, and $189 million and $167 million for the nine months ended September 30, 2024 and 2023, respectively.

ACQUISITIONS, GOODWILL, AND OTH

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	9 Months Ended
ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS ACQUISITIONS. MIM Software On April 1, 2024, the Company acquired 100% of the stock of MIM Software Inc. (“MIM Software”) for approximately $259 million, net of cash acquired, $13 million of potential earn-out payments, and up to $23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $195 million, customer-related intangible assets of $52 million, developed technology intangible assets of $48 million, net deferred tax liabilities of $19 million, and other net assets of $7 million. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. Revenue and earnings of MIM Software included in the Company’s financial statements since the acquisition date are not material to our consolidated revenue and earnings. If the acquisition of MIM Software had taken place as of the beginning of 2023, consolidated revenues and earnings would not have been significantly different from reported amounts. Caption Health On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million of future holdback payment, and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $94 million, intangible assets of $60 million, and deferred tax liabilities of $3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. GOODWILL. As discussed in Note 3, “Segment Information”, effective in the third quarter of 2024, the Company (1) reorganized its operations and moved responsibility for and reporting of IGT from the Imaging segment to the Ultrasound Segment and (2) renamed the Ultrasound segment the AVS segment. This resulted in a $1,031 million increase in the Company’s allocation of goodwill to its AVS segment and a corresponding decrease in the goodwill allocated to the Imaging segment. The Company allocated goodwill to its new reporting units using a relative fair value approach. Imaging AVS PCS PDx Total Balance at December 31, 2023 $ 4,431 $ 3,933 $ 2,038 $ 2,534 $ 12,936 Reallocation (1,031) 1,031 — — — Acquisitions 195 — — — 195 Foreign currency exchange and other 2 3 1 — 6 Balance at September 30, 2024 $ 3,598 $ 4,967 $ 2,039 $ 2,534 $ 13,138 We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. In connection with the change in reportable segments in the third quarter of 2024, the Company evaluated the goodwill of our Imaging and AVS reporting units for impairment before and after the segment realignment. There were no impairments identified as part of these assessments. In addition, with respect to the PCS and PDx reporting units, we did not identify any events or circumstances that required an interim impairment test since the last annual impairment testing date. OTHER INTANGIBLE ASSETS. Intangible assets decreased during the nine months ended September 30, 2024, primarily as a result of amortization, partially offset by additions related to the acquisition of MIM Software. Substantially all of our intangible assets are subject to amortization. Amortization expense was $77 million and $89 million for the three months ended September 30, 2024 and 2023, respectively, and $237 million and $278 million for the nine months ended September 30, 2024 and 2023, respectively.
ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS ACQUISITIONS. MIM Software On April 1, 2024, the Company acquired 100% of the stock of MIM Software Inc. (“MIM Software”) for approximately $259 million, net of cash acquired, $13 million of potential earn-out payments, and up to $23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $195 million, customer-related intangible assets of $52 million, developed technology intangible assets of $48 million, net deferred tax liabilities of $19 million, and other net assets of $7 million. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. Revenue and earnings of MIM Software included in the Company’s financial statements since the acquisition date are not material to our consolidated revenue and earnings. If the acquisition of MIM Software had taken place as of the beginning of 2023, consolidated revenues and earnings would not have been significantly different from reported amounts. Caption Health On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million of future holdback payment, and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $94 million, intangible assets of $60 million, and deferred tax liabilities of $3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. GOODWILL. As discussed in Note 3, “Segment Information”, effective in the third quarter of 2024, the Company (1) reorganized its operations and moved responsibility for and reporting of IGT from the Imaging segment to the Ultrasound Segment and (2) renamed the Ultrasound segment the AVS segment. This resulted in a $1,031 million increase in the Company’s allocation of goodwill to its AVS segment and a corresponding decrease in the goodwill allocated to the Imaging segment. The Company allocated goodwill to its new reporting units using a relative fair value approach. Imaging AVS PCS PDx Total Balance at December 31, 2023 $ 4,431 $ 3,933 $ 2,038 $ 2,534 $ 12,936 Reallocation (1,031) 1,031 — — — Acquisitions 195 — — — 195 Foreign currency exchange and other 2 3 1 — 6 Balance at September 30, 2024 $ 3,598 $ 4,967 $ 2,039 $ 2,534 $ 13,138 We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. In connection with the change in reportable segments in the third quarter of 2024, the Company evaluated the goodwill of our Imaging and AVS reporting units for impairment before and after the segment realignment. There were no impairments identified as part of these assessments. In addition, with respect to the PCS and PDx reporting units, we did not identify any events or circumstances that required an interim impairment test since the last annual impairment testing date. OTHER INTANGIBLE ASSETS. Intangible assets decreased during the nine months ended September 30, 2024, primarily as a result of amortization, partially offset by additions related to the acquisition of MIM Software. Substantially all of our intangible assets are subject to amortization. Amortization expense was $77 million and $89 million for the three months ended September 30, 2024 and 2023, respectively, and $237 million and $278 million for the nine months ended September 30, 2024 and 2023, respectively.

BORROWINGS

BORROWINGS	9 Months Ended
BORROWINGS	Sep. 30, 2024
Debt Disclosure [Abstract]
BORROWINGS	BORROWINGS The Company’s borrowings include the following senior unsecured notes and credit agreements: Senior Unsecured Notes The Company’s borrowings include $9,250 million aggregate principal amount of senior unsecured notes in seven series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”). This includes $1,000 million aggregate principal amount of 4.800% senior unsecured notes due in 2029 issued by the Company in the third quarter of 2024. Refer to the table below for further information about the Notes. Credit Facilities The Company has credit agreements providing for: • a five-year senior unsecured revolving credit facility in an aggregate committed amount of $2,500 million, maturing on January 3, 2028; • a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $1,000 million, maturing on December 11, 2024; and • a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million, maturing on January 2, 2026 (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”). There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $1,000 million and $1,150 million outstanding on the Term Loan Facility as of September 30, 2024 and December 31, 2023, respectively. In the first quarter of 2024, we repaid $150 million of the Term Loan Facility and had no principal debt repayments on the Notes in the nine months ended September 30, 2024. Borrowings Composition As of September 30, 2024 December 31, 2023 5.550% senior notes due November 15, 2024 $ 1,000 $ 1,000 5.600% senior notes due November 15, 2025 1,500 1,500 5.650% senior notes due November 15, 2027 1,750 1,750 4.800% senior notes due August 14, 2029 1,000 — 5.857% senior notes due March 15, 2030 1,250 1,250 5.905% senior notes due November 22, 2032 1,750 1,750 6.377% senior notes due November 22, 2052 1,000 1,000 Floating rate Term Loan Facility due January 2, 2026 1,000 1,150 Other 42 52 Total principal debt issued 10,292 9,452 Less: Unamortized debt issuance costs and discounts 36 35 Add: Cumulative basis adjustment for fair value hedges 57 25 Total borrowings 10,312 9,442 Less: Short-term borrowings (1) 1,007 1,006 Long-term borrowings $ 9,306 $ 8,436 (1) Short-term borrowings as of September 30, 2024 and December 31, 2023 i ncludes $1,004 million and $1,002 million, respectively, related to the current portion of our long-term borrowings, net of unamortized debt issuance costs and discounts. See Note 12, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated derivatives contracts. LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS. As of September 30, 2024 and December 31, 2023, the Company had bank guarantees and surety bonds of approximately $801 million and $751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $28 million and $39 million of guarantees as of September 30, 2024 and December 31, 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Condensed Consolidated Statements of Financial Position reflect a liability of $3 million and $4 million as of September 30, 2024 and December 31, 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 13, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE.

POSTRETIREMENT BENEFIT PLANS

POSTRETIREMENT BENEFIT PLANS	9 Months Ended
POSTRETIREMENT BENEFIT PLANS	Sep. 30, 2024
Retirement Benefits [Abstract]
POSTRETIREMENT BENEFIT PLANS	POSTRETIREMENT BENEFIT PLANS We sponsor a number of pension and retiree health and life insurance benefit plans that we present in three categories: Principal Pension Plans, Other Pension Plans, and Other Postretirement Plans (“OPEB Plans”). Please refer to Note 10, “Postretirement Benefit Plans” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 for further information. On January 1, 2024, we transitioned from legacy GE multiple-employer OPEB plans to GE HealthCare sponsored single-employer OPEB plans. This change did not have an impact on our results of operations or financial position. Pension plans with pension assets or obligations less than $50 million are not included in the results below. Components of Expense (Income) For the three months ended September 30 Principal Pension Plans Other Pension Plans OPEB 2024 2023 2024 2023 2024 2023 Service cost – Operating $ 7 $ 8 $ 6 $ 6 $ 2 $ 2 Interest cost 227 237 50 53 14 15 Expected return on plan assets (284) (292) (64) (65) — — Amortization of net loss (gain) (19) (30) 5 2 (15) (16) Amortization of prior service cost (credit) 2 1 — (1) (22) (22) Curtailment loss (gain) — 17 — — — — Non-operating $ (74) $ (67) $ (9) $ (11) $ (23) $ (23) Net periodic expense (income) $ (67) $ (58) $ (3) $ (5) $ (21) $ (21) For the nine months ended September 30 Principal Pension Plans Other Pension Plans OPEB Plans 2024 2023 2024 2023 2024 2023 Service cost – Operating $ 21 $ 25 $ 18 $ 18 $ 6 $ 6 Interest cost 681 715 150 157 41 45 Expected return on plan assets (851) (878) (190) (192) — — Amortization of net loss (gain) (57) (96) 15 7 (45) (48) Amortization of prior service cost (credit) 6 2 — (3) (66) (66) Curtailment loss (gain) — 17 — — — — Non-operating $ (221) $ (240) $ (25) $ (31) $ (70) $ (69) Net periodic expense (income) $ (200) $ (215) $ (7) $ (13) $ (64) $ (63) In the third quarter of 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees will be frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $17 million as non-operating benefit costs. In the nine months ended September 30, 2024, the Company made cash benefit payments totaling $91 million to its Principal Pension Plans, $67 million to its Other Pension Plans, and $99 million to its OPEB Plans. In 2024, the Company expects to make total cash contributions of approximately $336 million to these plans. The Company does not have a required minimum funding contribution for its U.S.-based GE HealthCare Pension Plan in 2024. Future contributions will depend on capital market conditions, including equity market returns, and other factors. Defined Contribution Plan GE HealthCare sponsors a defined contribution plan for its eligible U.S. employees . Expenses associated with

INCOME TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Our effective income tax rate was 25.5% and 39.3% for the three months ended September 30, 2024 and 2023, respectively, and 24.9% and 31.4% for the nine months ended September 30, 2024 and 2023, respectively. The tax rate for the three and nine months ended September 30, 2024 is higher than the U.S. statutory rate primarily due to the tax cost of global activities, reconciling adjustments to recorded tax account balances associated with the Spin-Off, withholding taxes, and state taxes, partially offset by research and development benefits. The effective tax rate for 2023 is higher than the U.S. statutory rate primarily due to the tax cost of global activities, including the U.S. taxation on international operations, tax effect of foreign currency movement, withholding taxes, and state taxes. Benefit (provision) for income taxes for the three and nine months ended September 30, 2023 included $105 million of deferred tax provision associated with the Tax Matters Agreement (“TMA”) with GE including the effect of completing the 2022 GE U.S. federal tax return. In addition, Other (income) expense – net for the three and nine months ended September 30, 2023 included a $30 million benefit related to changes in tax indemnities with GE also associated with the TMA and the effect of completing the 2022 GE U.S. federal tax return. Post Spin-Off, the Company’s previously undistributed earnings of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in the first quarter of 2023, an incremental deferred tax liability of $30 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. The Company is currently being audited in a number of jurisdictions for tax years 2004-2022, including China, Germany, Norway, the United Kingdom, and the United States.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET	9 Months Ended
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET	Sep. 30, 2024
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET Changes in Accumulated other comprehensive income (loss) ( “ AOCI”) by component, net of income taxes, were as follows. For the three months ended September 30, 2024 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI June 30, 2024 $ (1,812) $ 961 $ 6 $ (845) Other comprehensive income (loss) before reclassifications – net of taxes of $27, $8, and $10 177 (29) (34) 114 Reclassifications from AOCI – net of taxes (2) of $—, $12, and $1 — (38) (3) (41) Other comprehensive income (loss) 177 (67) (36) 74 Less: Other comprehensive income (loss) attributable to noncontrolling interests — — — — September 30, 2024 $ (1,635) $ 894 $ (30) $ (771) For the three months ended September 30, 2023 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI June 30, 2023 $ (1,757) $ 1,847 $ (20) $ 70 Other comprehensive income (loss) before reclassifications – net of taxes of $(16), $69, and $(6) (143) (214) 18 (339) Reclassifications from AOCI – net of taxes (2) of $—, $16, and $(1) — (50) 4 (46) Other comprehensive income (loss) (143) (264) 22 (385) Less: Other comprehensive income (loss) attributable to noncontrolling interests (35) — — (35) September 30, 2023 $ (1,865) $ 1,583 $ 2 $ (280) For the nine months ended September 30, 2024 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI December 31, 2023 $ (1,706) $ 1,033 $ (18) $ (691) Other comprehensive income (loss) before reclassifications – net of taxes of $13, $7, and $3 70 (27) (10) 33 Reclassifications from AOCI – net of taxes (2) of $—, $33, and $1 — (111) (3) (114) Other comprehensive income (loss) 70 (138) (12) (80) Less: Other comprehensive income (loss) attributable to noncontrolling interests — — — — September 30, 2024 $ (1,635) $ 894 $ (30) $ (771) For the nine months ended September 30, 2023 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI December 31, 2022 $ (1,845) $ (42) $ 9 $ (1,878) Other comprehensive income (loss) before reclassifications – net of taxes of $1, $60, and $(4) (84) (190) 10 (264) Reclassifications from AOCI – net of taxes (2) of $—, $49, and $5 — (156) (17) (173) Other comprehensive income (loss) (84) (346) (7) (437) Spin-Off related adjustments – net of taxes of $—, $(509), and $— 28 1,972 — 2,000 Less: Other comprehensive income (loss) attributable to noncontrolling interests (36) 1 — (35) September 30, 2023 $ (1,865) $ 1,583 $ 2 $ (280) (1) The amount of Currency translation adjustments recognized in Other comprehensive income (loss) (“OCI”) during the three and nine months ended September 30, 2024 and 2023 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “ Financial Instruments and Fair Value Measurements.” (2) Reclassifications from AOCI into earnings for Pension and Other Postretirement Plans are recognized within Non-operating benefit (income) costs, while Cash flow hedges are recognized within Cost of products and Cost of services in our Condensed Consolidated Statements of Income.

FINANCIAL INSTRUMENTS AND FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	9 Months Ended
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	Sep. 30, 2024
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS DERIVATIVES AND HEDGING. Our primary objective in executing and holding derivative contracts is to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, and equity prices. These derivative contracts reduce, but do not entirely eliminate, the aforementioned risks. Our policy is to use derivative contracts solely for managing risks and not for speculative purposes. Cash Flow Hedges For derivative instruments designated as cash flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings and to the same financial statement line item impacted by the hedged transaction. As of September 30, 2024, we expect to reclassify $35 million of pre-tax net deferred loss associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the impact on earnings of the related hedged transactions. The cash flows associated with derivatives designated as cash flow hedges are recorded in All other operating activities in the Condensed Consolidated Statements of Cash Flows. Net Investment Hedges We use cross-currency interest rate swaps and foreign currency forward contracts in combination with foreign currency option contracts to hedge the foreign currency risk associated with our net investment in foreign operations. As of September 30, 2024, these contracts were designated as hedges of our net investment in foreign operations, primarily in Euro and Chinese Renminbi currencies. The cash flows associated with derivatives designated as net investment hedges are recorded in All other investing activities in the Condensed Consolidated Statements of Cash Flows. For the nine months ended September 30, 2024, All other investing activities includes a $94 million payment for the settlement of cross-currency swaps that were designated in net investment hedges. Cash flows from the periodic interest settlements on the cross-currency swaps are recorded in All other operating activities in the Condensed Consolidated Statements of Cash Flows. Fair Value Hedges We use interest rate swaps to hedge the interest rate risk on our fixed rate borrowings. These derivatives are designated as fair value hedges to hedge the changes in fair value due to benchmark interest rate risk of specific designated cash flows of our senior unsecured notes. We record the changes in fair value on these swap contracts in Interest and other financial charges – net in our Condensed Consolidated Statements of Income, the same line item where the offsetting change in the fair value of the designated cash flows of the senior unsecured note is recorded as a basis adjustment. Cash flows for the periodic interest settlements on the interest rate swaps are recorded in All other operating activities in the Condensed Consolidated Statements of Cash Flows. Derivatives Not Designated as Hedging Instrument s We also execute derivative instruments, such as foreign currency forward contracts and equity-linked total return swaps, which are not designated as qualifying hedges. These derivatives serve as economic hedges of foreign currency exchange rate and equity price risks. We also identify and record foreign currency-related features in our purchase or sales contracts where the currency is not the local or functional currency of any substantive party to the contract and record them as embedded derivatives. The changes in fair value of derivatives not designated in qualifying hedge transactions are recorded in Cost of products, Cost of services, Selling, general, and administrative (“SG&A”), and Other (income) expense – net in the Condensed Consolidated Statements of Income based on the nature of the underlying hedged transaction. Changes in fair value of embedded derivatives are recognized in Other (income) expense – net in the Condensed Consolidated Statements of Income. The cash flows associated with derivatives not designated but used as economic hedges are recorded, based on the nature of the underlying hedged transaction, in All other operating activities and All other investing activities in the Condensed Consolidated Statements of Cash Flows. The cash flows related to embedded derivatives are included in All other operating activities in the Condensed Consolidated Statements of Cash Flows. The following table presents the gross fair values of our outstanding derivative instruments. Fair Value of Derivatives September 30, 2024 December 31, 2023 Gross Notional Fair Value – Assets Fair Value – Liabilities Gross Notional Fair Value – Assets Fair Value – Liabilities Foreign currency forward contracts $ 1,504 $ 2 $ 42 $ 1,356 $ 8 $ 30 Derivatives accounted for as cash flow hedges 1,504 2 42 1,356 8 30 Cross-currency swaps (1) 2,148 18 174 2,209 — 204 Foreign currency forward and options contracts 1,625 17 20 991 9 11 Derivatives accounted for as net investment hedges 3,773 35 195 3,200 9 215 Interest rate swaps (1) 1,700 61 5 1,000 35 10 Derivatives accounted for as fair value hedges 1,700 61 5 1,000 35 10 Foreign currency forward contracts 3,854 33 13 3,597 19 12 Other derivatives (1)(2) 397 37 3 438 57 2 Derivatives not designated as hedging instruments 4,251 70 16 4,035 76 14 Total derivatives $ 11,229 $ 168 $ 257 $ 9,591 $ 128 $ 269 (1) Accrued interest was immaterial for the periods presented and is excluded from fair value. These amounts are recognized within All other current assets and All other current liabilities in the Condensed Consolidated Statements of Financial Position. (2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts. As of December 31, 2023, Other derivatives also included commodity contracts. The following table presents amounts recorded in Long-term borrowings in the Condensed Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges. September 30, 2024 December 31, 2023 Carrying amount Cumulative basis adjustment included in the carrying amount Carrying amount Cumulative basis adjustment included in the carrying amount Long-term borrowings designated in fair value hedges $ 1,753 $ 57 $ 1,023 $ 25 Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis in our Condensed Consolidated Statements of Financial Position and in the table above. As of September 30, 2024 and December 31, 2023, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $85 million and $41 million, respectively. The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges. Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Cash flow hedges $ (43) $ 24 $ (13) $ 14 Net investment hedges (1) (116) 64 (57) (7) (1) Amounts recognized in OCI for excluded components for the periods presented were immaterial. The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Condensed Consolidated Statements of Income. Derivative Financial Instruments and Hedging Activity For the three months ended September 30, 2024 Cost of products Cost of services SG&A Interest and other financial charges – net Other (4) Foreign currency forward contracts $ 3 $ 1 $ — $ — $ — Effects of cash flow hedges 3 1 — — — Cross-currency swaps — — — 7 — Foreign currency forward and options contracts — — — 4 — Effects of net investment hedges (1) — — — 11 — Interest rate swaps (2) — — — 76 — Debt basis adjustment on Long-term borrowings — — — (84) — Effects of fair value hedges — — — (7) — Foreign currency forward contracts 28 7 — — — Other derivatives (3) — — 2 — 5 Effects of derivatives not designated as hedging instruments 28 7 2 — 5 For the three months ended September 30, 2023 Cost of products Cost of services SG&A Interest and other financial charges – net Other (4) Foreign currency forward contracts $ (5) $ (1) $ — $ — $ — Effects of cash flow hedges (5) (1) — — — Cross-currency swaps — — — 8 — Foreign currency forward and option contracts — — — 1 1 Effects of net investment hedges (1) — — — 9 1 Interest rate swaps — — — — — Debt basis adjustment on Long-term borrowings — — — — — Effects of fair value hedges — — — — — Foreign currency forward contracts (38) (9) — — 4 Other derivatives (3) — — (2) — 10 Effects of derivatives not designated as hedging instruments (38) (9) (2) — 14 For the nine months ended September 30, 2024 Cost of products Cost of services SG&A Interest and other financial charges – net Other (4) Foreign currency forward contracts $ 3 $ 1 $ — $ — $ — Effects of cash flow hedges 3 1 — — — Cross-currency swaps — — — 24 — Foreign currency forward and options contracts — — — 8 — Effects of net investment hedges (1) — — — 32 — Interest rate swaps (2) — — — 11 — Debt basis adjustment on Long-term borrowings — — — (31) — Effects of fair value hedges — — — (21) — Foreign currency forward contracts 21 5 — — — Other derivatives (3) — — 7 — 28 Effects of derivatives not designated as hedging instruments 21 5 7 — 28 For the nine months ended September 30, 2023 Cost of products Cost of services SG&A Interest and other financial charges – net Other (4) Foreign currency forward contracts $ 18 $ 4 $ — $ — $ — Effects of cash flow hedges 18 4 — — — Cross-currency swaps — — — 25 — Foreign currency forward and option contracts — — — 1 1 Effects of net investment hedges (1) — — — 26 1 Interest rate swaps — — — — — Debt basis adjustment on Long-term borrowings — — — — — Effects of fair value hedges — — — — — Foreign currency forward contracts (28) (6) — — 10 Other derivatives (3) — — 5 — 36 Effects of derivatives not designated as hedging instruments (28) (6) 5 — 46 (1) Changes in fair value related to components other than the spot rate are excluded from effectiveness testing for the three and nine months ended September 30, 2024 and 2023. (2) Amount includes $(7) million and $(21) million of interest expense on interest rate derivatives for the three and nine months ended September 30, 2024, respectively. (3) Other derivatives are primarily comprised of embedded derivatives and derivatives related to equity contracts. (4) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Condensed Consolidated Statements of Income. FAIR VALUE MEASUREMENTS. The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis. Fair Value of Assets and Liabilities Measured on a Recurring Basis As of September 30, 2024 As of December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Money market funds $ — $ 231 $ — $ 231 $ — $ 200 $ — $ 200 Investment securities 26 — — 26 31 — — 31 Derivatives — 168 — 168 — 128 — 128 Liabilities: Derivatives — 257 — 257 — 269 — 269 Contingent consideration — — 35 35 — — 44 44 Cash equivalents As of September 30, 2024 and December 31, 2023, Cash, cash equivalents, and restricted cash of $3,568 million and $2,504 million, respectively, included money market funds of $231 million and $200 million, and other cash equivalents of $2,303 million and $1,023 million, respectively. The carrying values of the other cash equivalents approximates the fair value due to their short maturities and are valued using Level 1 or Level 2 inputs. Refer to Note 16, “Supplemental Financial Information” for further information. Derivatives Derivatives are measured at fair value using a discounted cash flow method or option models using interest rates, foreign exchange spot and forward rates and yield curves observable at commonly quoted intervals, implied volatilities, and credit spreads as key inputs. Unobservable inputs relate to our own credit risk which is not significant to the overall measurement of fair value. Contingent consideration Contingent consideration is recorded at fair value based on estimates of future cash flows in connection with business acquisitions . As the valuation of these liabilities is based on inputs that are less observable or not observable in the market, the determination of fair value is classified within Level 3 of the fair value hierarchy. Non-recurring fair value measurements Changes in fair value measurements of assets and liabilities measured at fair value on a non-recurring basis, such as equity method investments, equity investments without readily determinable fair value, financing receivables, and long-lived assets, were not material for the nine months ended September 30, 2024 and 2023. Fair value of other financial instruments The estimated fair value of borrowings as of September 30, 2024 and December 31, 2023 was $10,937 million and $9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $10,312 million and $9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 8, “Borrowings” and Note 16, “Supplemental Financial Information” for further information.

COMMITMENTS, GUARANTEES, PRODUC

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES	COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES GUARANTEES. The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 8, “Borrowings” for further information. Following the Spin-Off, which was completed pursuant to the Separation and Distribution Agreement, the Company had remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE was obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could have been obligated to make payments under the applicable instruments for which GE was obligated to reimburse and indemnify the Company. As of December 31, 2023, the Company’s maximum aggregate exposure, subject to GE reimbursement, was approximately $114 million. In the second quarter of 2024, these remaining performance guarantees were all terminated or replaced. PRODUCT WARRANTIES. We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows. For the nine months ended September 30 2024 2023 Balance at beginning of period $ 192 $ 193 Current-year provisions 143 158 Expenditures (166) (159) Other changes (1) (3) Balance at end of period $ 168 $ 189 Product warranties are recognized within All other current liabilities in the Condensed Consolidated Statements of Financial Position. LEGAL MATTERS. In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matters described below that could have a material impact on our results of operations and cash flows. In many proceedings, including the specific matters described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated. Contracts with Iraqi Ministry of Health In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (the “D.C. Circuit”). In February 2023, the D.C. Circuit denied this request. In June 2023, defendants petitioned the Supreme Court to review the D.C. Circuit’s decision. On June 24, 2024, the Supreme Court vacated the D.C. Circuit’s decision and remanded the case to the D.C. Circuit for further consideration in light of Twitter, Inc. v. Taamneh , a separate case decided by the Supreme Court in May 2023. The proceedings in the District Court are currently inactive. Government Disclosures From time to time, we make self-disclosures regarding our compliance with the Foreign Corrupt Practices Act (“FCPA”) and similar laws to relevant authorities who may pursue or decline to pursue enforcement proceedings against us. We, with the assistance of outside counsel, made voluntary self-disclosures to the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”) beginning in 2018 regarding tender irregularities and other potential violations of the FCPA relating to our activities in certain provinces in China. We have been engaged in ongoing discussions with each of the SEC and the DOJ regarding these matters. We are fully cooperating with the reviews by these agencies and have implemented, and continue to implement, enhancements to our compliance policies and practices. At this time, we are unable to predict the duration, scope, result, or related costs associated with these disclosures to the SEC and the DOJ. We also are unable to predict what, if any, action may be taken by the SEC or the DOJ or what penalties or remedial actions they may seek. Any determination that our operations or activities are not in compliance with existing laws or regulations, including applicable foreign laws, could result in the imposition of fines, penalties, disgorgement, equitable relief, or other losses.

RESTRUCTURING ACTIVITIES

RESTRUCTURING ACTIVITIES	9 Months Ended
RESTRUCTURING ACTIVITIES	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
RESTRUCTURING ACTIVITIES	RESTRUCTURING ACTIVITIES Restructuring activities are essential to optimize the business operating model for GE HealthCare and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring charges (gains) primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and cease-use costs. For segment reporting, restructuring activities are not allocated. Net expenses for restructuring initiatives committed to by management through September 30, 2024 are included in the table below. Restructuring Activities For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Employee termination costs $ 19 $ 1 $ 61 $ 26 Facility and other exit costs 2 1 15 2 Asset write-downs 1 1 14 6 Total restructuring activities – net $ 22 $ 3 $ 90 $ 34 These restructuring initiatives are expected to result in additional expenses of approximately $21 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Condensed Consolidated Statements of Income.

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
EARNINGS PER SHARE	Sep. 30, 2024
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The numerator for both basic and diluted earnings per share (“EPS”) is Net income attributable to GE HealthCare common stockholders. The denominator of basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units, and performance share units is reflected in the denominator for diluted EPS using the treasury stock method. Earnings Per Share For the three months ended September 30 For the nine months ended September 30 (In millions, except per share amounts) 2024 2023 2024 2023 Numerator: Net income from continuing operations $ 490 $ 386 $ 1,312 $ 1,202 Net (income) loss attributable to noncontrolling interests (19) (7) (40) (33) Net income from continuing operations attributable to GE HealthCare 470 379 1,272 1,169 Deemed preferred stock dividend of redeemable noncontrolling interest — — — (183) Net income from continuing operations attributable to GE HealthCare common stockholders 470 379 1,272 986 Income (loss) from discontinued operations, net of taxes — (4) — (4) Net income attributable to GE HealthCare common stockholders $ 470 $ 375 $ 1,272 $ 982 Denominator: Basic weighted-average shares outstanding 457 455 456 455 Dilutive effect of common stock equivalents 2 3 2 3 Diluted weighted-average shares outstanding 459 458 459 458 Basic Earnings Per Share: Continuing operations $ 1.03 $ 0.83 $ 2.79 $ 2.17 Discontinued operations — (0.01) — (0.01) Attributable to GE HealthCare common stockholders 1.03 0.82 2.79 2.16 Diluted Earnings Per Share: Continuing operations $ 1.02 $ 0.83 $ 2.77 $ 2.16 Discontinued operations — (0.01) — (0.01) Attributable to GE HealthCare common stockholders 1.02 0.82 2.77 2.15 Antidilutive securities (1) 2 4 4 4 (1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION	9 Months Ended
SUPPLEMENTAL FINANCIAL INFORMATION	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTAL FINANCIAL INFORMATION	SUPPLEMENTAL FINANCIAL INFORMATION Cash, Cash Equivalents, and Restricted Cash As of September 30, 2024 December 31, 2023 Cash and cash equivalents (1) $ 3,550 $ 2,494 Short-term restricted cash 18 10 Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position 3,568 2,504 Long-term restricted cash (2) 4 2 Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows $ 3,572 $ 2,506 (1) The increase in cash and cash equivalents was primarily due to proceeds from the issuance of senior unsecured notes by the Company in the third quarter of 2024. Refer to Note 8, “Borrowings” for further information. (2) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. Inventories As of September 30, 2024 December 31, 2023 Raw materials $ 992 $ 961 Work in process 100 91 Finished goods 1,032 908 Inventories (1) $ 2,124 $ 1,960 (1) Certain inventory items are long-term in nature and therefore have been recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. Property, Plant, and Equipment – Net As of September 30, 2024 December 31, 2023 Original cost $ 5,356 $ 5,208 Accumulated depreciation (3,176) (3,064) Right-of-use operating lease assets, net of amortization 359 356 Property, plant, and equipment – net $ 2,539 $ 2,500 All Other Current and Non-Current Assets As of September 30, 2024 December 31, 2023 Prepaid expenses and deferred costs $ 197 $ 147 Financing receivables – net 94 97 Derivative instruments 114 84 Other (1) 72 61 All other current assets $ 476 $ 389 Prepaid pension asset $ 797 $ 716 Equity method and other investments 361 357 Financing receivables – net 178 178 Long-term receivables – net 167 124 Inventories 151 147 Contract and other deferred assets 189 168 Other (2) 255 191 All other non-current assets $ 2,098 $ 1,881 (1) Current Other primarily consists of tax receivables. (2) Non-current Other primarily consists of derivative instruments, indemnity assets associated with separation agreements with GE, capitalized costs associated with cloud computing arrangements, and tax receivables. All Other Current and Non-Current Liabilities As of September 30, 2024 December 31, 2023 Sales allowances and related liabilities $ 215 $ 228 Income and indirect tax liabilities including uncertain tax positions 160 260 Product warranties 168 192 Accrued freight and utilities 127 132 Operating lease liabilities 114 110 Derivative instruments (1) 84 128 Interest payable on borrowings 164 87 Environmental and asset retirement obligations 19 21 Other (2) 356 335 All other current liabilities $ 1,409 $ 1,493 Contract liabilities $ 704 $ 705 Operating lease liabilities 263 273 Environmental and asset retirement obligations 306 265 Income and indirect tax liabilities including uncertain tax positions 205 208 Derivative instruments 183 136 Finance lease obligations 43 38 Sales allowances and related liabilities 23 27 Other (3) 195 225 All other non-current liabilities $ 1,920 $ 1,877 (1) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information. (2) Current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and dividends payable to stockholders. (3) Non-current Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities. SUPPLY CHAIN FINANCE PROGRAMS. The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables as borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 180 days, depending on the underlying supplier agreements. Included within Accounts payable in the Condensed Consolidated Statements of Financial Position as of September 30, 2024 and December 31, 2023 were $403 million and $365 million, respectively, of confirmed supplier invoices that are outstanding and subject to third-party programs. REDEEMABLE NONCONTROLLING INTERESTS . The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Condensed Consolidated Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable, or probable of becoming redeemable, are subsequently adjusted to the greater of current redemption value or initial carrying value. The activity attributable to redeemable noncontrolling interests for the nine months ended September 30, 2024 and 2023 is presented below. Redeemable Noncontrolling Interests For the nine months ended September 30 2024 2023 Balance at beginning of period $ 165 $ 230 Net income attributable to redeemable noncontrolling interests 35 28 Redemption value adjustments (1) — 183 Distributions to and exercise of redeemable noncontrolling interests and other (2) (23) (280) Balance at end of period $ 177 $ 161 (1) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. As a result, these redeemable noncontrolling interests were remeasured to their current redemption value. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to Retained earnings in the Condensed Consolidated Statements of Financial Position. (2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $211 million was paid in the second quarter of 2023. Other Income (Expense) – Net For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Net financing income and investment income (loss) $ 5 $ 6 $ (11) $ 19 Equity method income (loss) 2 — 5 9 Change in fair value of assumed obligations (9) (5) (26) (24) Other items, net (1) 11 62 33 81 Total other income (expense) – net $ 9 $ 63 $ 1 $ 85 (1) Other items, net primarily consists of government grants, lease income, gains and losses related to derivatives, and licensing and royalty income for the three and nine months ended September 30, 2024, and change in tax indemnity, gains and losses related to derivatives, licensing and royalty income, and lease income for the three and nine months ended September 30, 2023.

RELATED PARTIES AND TRANSITION

RELATED PARTIES AND TRANSITION SERVICES AGREEMENT	9 Months Ended
RELATED PARTIES AND TRANSITION SERVICES AGREEMENT	Sep. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTIES AND TRANSITION SERVICES AGREEMENT	RELATED PARTIES AND TRANSITION SERVICES AGREEMENT In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE, including the Transition Services Agreement (“TSA”). These agreements were structured in anticipation of GE’s transaction to separate the GE Vernova business as described in Note 1, “Organization and Basis of Presentation.” Under these agreements, we incurred $40 million, net, and $94 million, net, for the three months ende d September 30, 2024 and 2023, respectively, and $138 million, net, and $286 million, net, for the nine months ended September 30, 2024 and 2023, respectively. These amounts represent fees charged from GE and GE Vernova to the Company, the majority of which are related to information technology, and are net of fees charged from the Company to GE and GE Vernova for facilities and other shared services. For more information on these agreements, see Note 19, “Related Parties” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net income attributable to GE HealthCare	$ 470	$ 375	$ 1,272	$ 1,165

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

ORGANIZATION AND BASIS OF PRE_2

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	9 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION (Policies)	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	The condensed consolidated financial statements (the “financial statements”) have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the financial statements. Operating results for the three and nine months ended September 30, 2024 and 2023 are not necessarily indicative of the results that may be expected for the fiscal year as a whole. The December 31, 2023 period presented on the Condensed Consolidated Statement of Financial Position was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.
RECLASSIFICATION	Certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year presentation, which provides additional detail to readers of the financial statements. Amounts related to current compensation and benefit obligations that were previously reported within the All other current liabilities and All other operating activities lines on the Condensed Consolidated Statements of Financial Position and Statements of Cash Flows, respectively, have been reclassified to separate lines on the respective financial statements. Additionally on the Condensed Consolidated Statements of Cash Flows, amounts related to purchase of investments previously reported within All other investing activities, and amounts related to equity award activity previously reported within All other financing activities, have been reclassified to separate lines.
ESTIMATES AND ASSUMPTIONS	ESTIMATES AND ASSUMPTIONS. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS. In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect that ASU 2023-07 will have on our financial statement disclosures. In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures . ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect that ASU 2023-09 will have on our financial statement disclosures.

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	9 Months Ended
REVENUE RECOGNITION (Tables)	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Summary of Contract and Other Deferred Assets	Contract and Other Deferred Assets As of September 30, 2024 December 31, 2023 Contract assets $ 685 $ 600 Other deferred assets 361 400 Contract and other deferred assets 1,046 1,000 Non-current contract assets (1) 93 72 Non-current other deferred assets (1) 96 96 Total contract and other deferred assets $ 1,235 $ 1,168 (1) Non-current contract and other deferred assets are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
SEGMENT INFORMATION (Tables)	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	Total Revenues by Segment For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Total Imaging $ 2,229 $ 2,236 $ 6,462 $ 6,552 AVS: Procedural Guidance 647 641 1,967 1,938 Specialized Ultrasound 569 573 1,725 1,774 Total AVS 1,216 1,214 3,692 3,712 PCS: Monitoring Solutions 556 573 1,621 1,688 Life Support Solutions 223 191 677 627 Total PCS 779 764 2,298 2,315 Total PDx 625 589 1,862 1,715 Other (1) 15 19 39 52 Total revenues $ 4,863 $ 4,822 $ 14,353 $ 14,346 (1) Financial information not presented within the reportable segments, shown within the Other category, represents Hea lthCar e Financial Services (“HFS”) which does not meet the definition of an operating segment. Segment EBIT For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Segment EBIT Imaging $ 287 $ 243 $ 660 $ 566 AVS 232 254 744 798 PCS 82 80 241 273 PDx 193 166 571 473 Other (1) 1 1 2 9 795 744 2,217 2,119 Restructuring costs (22) (3) (90) (34) Acquisition and disposition-related benefits (charges) 4 14 7 15 Gain (loss) on business and asset dispositions (1) — — — Spin-Off and separation costs (56) (45) (182) (175) Amortization of acquisition-related intangible assets (34) (32) (100) (95) Investment revaluation gain (loss) (1) 2 (26) 1 Interest and other financial charges – net (130) (138) (383) (411) Non-operating benefit income (costs) 102 94 306 332 Income before income taxes $ 658 $ 636 $ 1,747 $ 1,752 (1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS which does not meet the definition of an operating segment.

RECEIVABLES (Tables)

RECEIVABLES (Tables)	9 Months Ended
RECEIVABLES (Tables)	Sep. 30, 2024
Receivables [Abstract]
Schedule of Receivables	Current Receivables As of September 30, 2024 December 31, 2023 Current customer receivables (1) $ 3,265 $ 3,339 Non-income based tax receivables 139 166 Other sundry receivables 119 118 Current sundry receivables 257 284 Allowance for credit losses (104) (98) Total current receivables – net $ 3,418 $ 3,525 (1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $135 million and $144 million as of September 30, 2024 and December 31, 2023, respectively. Long-Term Receivables As of September 30, 2024 December 31, 2023 Long-term customer receivables $ 72 $ 55 Non-income based tax receivables 23 26 Other sundry receivables 102 73 Long-term sundry receivables 125 99 Allowance for credit losses (30) (30) Total long-term receivables – net (1) $ 167 $ 124 (1) Long-term receivables are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. As of September 30, 2024 December 31, 2023 Loans receivable, at amortized cost $ 23 $ 29 Investment in financing leases, net of deferred income 74 71 Allowance for credit losses (3) (3) Current financing receivables – net (1) 94 97 Loans receivable, at amortized cost 32 37 Investment in financing leases, net of deferred income 151 146 Allowance for credit losses (5) (5) Non-current financing receivables – net (1) $ 178 $ 178 (1) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Condensed Consolidated Statements of Financial Position.

FINANCING RECEIVABLES (Tables)

FINANCING RECEIVABLES (Tables)	9 Months Ended
FINANCING RECEIVABLES (Tables)	Sep. 30, 2024
Receivables [Abstract]
Schedule of Receivables	Current Receivables As of September 30, 2024 December 31, 2023 Current customer receivables (1) $ 3,265 $ 3,339 Non-income based tax receivables 139 166 Other sundry receivables 119 118 Current sundry receivables 257 284 Allowance for credit losses (104) (98) Total current receivables – net $ 3,418 $ 3,525 (1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $135 million and $144 million as of September 30, 2024 and December 31, 2023, respectively. Long-Term Receivables As of September 30, 2024 December 31, 2023 Long-term customer receivables $ 72 $ 55 Non-income based tax receivables 23 26 Other sundry receivables 102 73 Long-term sundry receivables 125 99 Allowance for credit losses (30) (30) Total long-term receivables – net (1) $ 167 $ 124 (1) Long-term receivables are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position. As of September 30, 2024 December 31, 2023 Loans receivable, at amortized cost $ 23 $ 29 Investment in financing leases, net of deferred income 74 71 Allowance for credit losses (3) (3) Current financing receivables – net (1) 94 97 Loans receivable, at amortized cost 32 37 Investment in financing leases, net of deferred income 151 146 Allowance for credit losses (5) (5) Non-current financing receivables – net (1) $ 178 $ 178 (1) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Condensed Consolidated Statements of Financial Position.

ACQUISITIONS, GOODWILL, AND O_2

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The Company allocated goodwill to its new reporting units using a relative fair value approach. Imaging AVS PCS PDx Total Balance at December 31, 2023 $ 4,431 $ 3,933 $ 2,038 $ 2,534 $ 12,936 Reallocation (1,031) 1,031 — — — Acquisitions 195 — — — 195 Foreign currency exchange and other 2 3 1 — 6 Balance at September 30, 2024 $ 3,598 $ 4,967 $ 2,039 $ 2,534 $ 13,138

BORROWINGS (Tables)

BORROWINGS (Tables)	9 Months Ended
BORROWINGS (Tables)	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Long-Term Borrowings	Borrowings Composition As of September 30, 2024 December 31, 2023 5.550% senior notes due November 15, 2024 $ 1,000 $ 1,000 5.600% senior notes due November 15, 2025 1,500 1,500 5.650% senior notes due November 15, 2027 1,750 1,750 4.800% senior notes due August 14, 2029 1,000 — 5.857% senior notes due March 15, 2030 1,250 1,250 5.905% senior notes due November 22, 2032 1,750 1,750 6.377% senior notes due November 22, 2052 1,000 1,000 Floating rate Term Loan Facility due January 2, 2026 1,000 1,150 Other 42 52 Total principal debt issued 10,292 9,452 Less: Unamortized debt issuance costs and discounts 36 35 Add: Cumulative basis adjustment for fair value hedges 57 25 Total borrowings 10,312 9,442 Less: Short-term borrowings (1) 1,007 1,006 Long-term borrowings $ 9,306 $ 8,436 (1) Short-term borrowings as of September 30, 2024 and December 31, 2023 i ncludes $1,004 million and $1,002 million, respectively, related to the current portion of our long-term borrowings, net of unamortized debt issuance costs and discounts.

POSTRETIREMENT BENEFIT PLANS (T

POSTRETIREMENT BENEFIT PLANS (Tables)	9 Months Ended
POSTRETIREMENT BENEFIT PLANS (Tables)	Sep. 30, 2024
Retirement Benefits [Abstract]
Components of Net Periodic Expense	Components of Expense (Income) For the three months ended September 30 Principal Pension Plans Other Pension Plans OPEB 2024 2023 2024 2023 2024 2023 Service cost – Operating $ 7 $ 8 $ 6 $ 6 $ 2 $ 2 Interest cost 227 237 50 53 14 15 Expected return on plan assets (284) (292) (64) (65) — — Amortization of net loss (gain) (19) (30) 5 2 (15) (16) Amortization of prior service cost (credit) 2 1 — (1) (22) (22) Curtailment loss (gain) — 17 — — — — Non-operating $ (74) $ (67) $ (9) $ (11) $ (23) $ (23) Net periodic expense (income) $ (67) $ (58) $ (3) $ (5) $ (21) $ (21) For the nine months ended September 30 Principal Pension Plans Other Pension Plans OPEB Plans 2024 2023 2024 2023 2024 2023 Service cost – Operating $ 21 $ 25 $ 18 $ 18 $ 6 $ 6 Interest cost 681 715 150 157 41 45 Expected return on plan assets (851) (878) (190) (192) — — Amortization of net loss (gain) (57) (96) 15 7 (45) (48) Amortization of prior service cost (credit) 6 2 — (3) (66) (66) Curtailment loss (gain) — 17 — — — — Non-operating $ (221) $ (240) $ (25) $ (31) $ (70) $ (69) Net periodic expense (income) $ (200) $ (215) $ (7) $ (13) $ (64) $ (63)

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in Accumulated other comprehensive income (loss) ( “ AOCI”) by component, net of income taxes, were as follows. For the three months ended September 30, 2024 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI June 30, 2024 $ (1,812) $ 961 $ 6 $ (845) Other comprehensive income (loss) before reclassifications – net of taxes of $27, $8, and $10 177 (29) (34) 114 Reclassifications from AOCI – net of taxes (2) of $—, $12, and $1 — (38) (3) (41) Other comprehensive income (loss) 177 (67) (36) 74 Less: Other comprehensive income (loss) attributable to noncontrolling interests — — — — September 30, 2024 $ (1,635) $ 894 $ (30) $ (771) For the three months ended September 30, 2023 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI June 30, 2023 $ (1,757) $ 1,847 $ (20) $ 70 Other comprehensive income (loss) before reclassifications – net of taxes of $(16), $69, and $(6) (143) (214) 18 (339) Reclassifications from AOCI – net of taxes (2) of $—, $16, and $(1) — (50) 4 (46) Other comprehensive income (loss) (143) (264) 22 (385) Less: Other comprehensive income (loss) attributable to noncontrolling interests (35) — — (35) September 30, 2023 $ (1,865) $ 1,583 $ 2 $ (280) For the nine months ended September 30, 2024 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI December 31, 2023 $ (1,706) $ 1,033 $ (18) $ (691) Other comprehensive income (loss) before reclassifications – net of taxes of $13, $7, and $3 70 (27) (10) 33 Reclassifications from AOCI – net of taxes (2) of $—, $33, and $1 — (111) (3) (114) Other comprehensive income (loss) 70 (138) (12) (80) Less: Other comprehensive income (loss) attributable to noncontrolling interests — — — — September 30, 2024 $ (1,635) $ 894 $ (30) $ (771) For the nine months ended September 30, 2023 Currency translation adjustments (1) Pension and Other Postretirement Plans Cash flow hedges Total AOCI December 31, 2022 $ (1,845) $ (42) $ 9 $ (1,878) Other comprehensive income (loss) before reclassifications – net of taxes of $1, $60, and $(4) (84) (190) 10 (264) Reclassifications from AOCI – net of taxes (2) of $—, $49, and $5 — (156) (17) (173) Other comprehensive income (loss) (84) (346) (7) (437) Spin-Off related adjustments – net of taxes of $—, $(509), and $— 28 1,972 — 2,000 Less: Other comprehensive income (loss) attributable to noncontrolling interests (36) 1 — (35) September 30, 2023 $ (1,865) $ 1,583 $ 2 $ (280) (1) The amount of Currency translation adjustments recognized in Other comprehensive income (loss) (“OCI”) during the three and nine months ended September 30, 2024 and 2023 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “ Financial Instruments and Fair Value Measurements.” (2) Reclassifications from AOCI into earnings for Pension and Other Postretirement Plans are recognized within Non-operating benefit (income) costs, while Cash flow hedges are recognized within Cost of products and Cost of services in our Condensed Consolidated Statements of Income.

FINANCIAL INSTRUMENTS AND FAI_2

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Derivative Assets at Fair Value	The following table presents the gross fair values of our outstanding derivative instruments. Fair Value of Derivatives September 30, 2024 December 31, 2023 Gross Notional Fair Value – Assets Fair Value – Liabilities Gross Notional Fair Value – Assets Fair Value – Liabilities Foreign currency forward contracts $ 1,504 $ 2 $ 42 $ 1,356 $ 8 $ 30 Derivatives accounted for as cash flow hedges 1,504 2 42 1,356 8 30 Cross-currency swaps (1) 2,148 18 174 2,209 — 204 Foreign currency forward and options contracts 1,625 17 20 991 9 11 Derivatives accounted for as net investment hedges 3,773 35 195 3,200 9 215 Interest rate swaps (1) 1,700 61 5 1,000 35 10 Derivatives accounted for as fair value hedges 1,700 61 5 1,000 35 10 Foreign currency forward contracts 3,854 33 13 3,597 19 12 Other derivatives (1)(2) 397 37 3 438 57 2 Derivatives not designated as hedging instruments 4,251 70 16 4,035 76 14 Total derivatives $ 11,229 $ 168 $ 257 $ 9,591 $ 128 $ 269 (1) Accrued interest was immaterial for the periods presented and is excluded from fair value. These amounts are recognized within All other current assets and All other current liabilities in the Condensed Consolidated Statements of Financial Position. (2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts. As of December 31, 2023, Other derivatives also included commodity contracts.
Schedule of Derivative Liabilities at Fair Value	The following table presents the gross fair values of our outstanding derivative instruments. Fair Value of Derivatives September 30, 2024 December 31, 2023 Gross Notional Fair Value – Assets Fair Value – Liabilities Gross Notional Fair Value – Assets Fair Value – Liabilities Foreign currency forward contracts $ 1,504 $ 2 $ 42 $ 1,356 $ 8 $ 30 Derivatives accounted for as cash flow hedges 1,504 2 42 1,356 8 30 Cross-currency swaps (1) 2,148 18 174 2,209 — 204 Foreign currency forward and options contracts 1,625 17 20 991 9 11 Derivatives accounted for as net investment hedges 3,773 35 195 3,200 9 215 Interest rate swaps (1) 1,700 61 5 1,000 35 10 Derivatives accounted for as fair value hedges 1,700 61 5 1,000 35 10 Foreign currency forward contracts 3,854 33 13 3,597 19 12 Other derivatives (1)(2) 397 37 3 438 57 2 Derivatives not designated as hedging instruments 4,251 70 16 4,035 76 14 Total derivatives $ 11,229 $ 168 $ 257 $ 9,591 $ 128 $ 269 (1) Accrued interest was immaterial for the periods presented and is excluded from fair value. These amounts are recognized within All other current assets and All other current liabilities in the Condensed Consolidated Statements of Financial Position. (2) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts. As of December 31, 2023, Other derivatives also included commodity contracts.
Schedule of Effect of Derivatives Instruments on Statement of Financial Position and Statement of Income	The following table presents amounts recorded in Long-term borrowings in the Condensed Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges. September 30, 2024 December 31, 2023 Carrying amount Cumulative basis adjustment included in the carrying amount Carrying amount Cumulative basis adjustment included in the carrying amount Long-term borrowings designated in fair value hedges $ 1,753 $ 57 $ 1,023 $ 25 The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Condensed Consolidated Statements of Income. Derivative Financial Instruments and Hedging Activity For the three months ended September 30, 2024 Cost of products Cost of services SG&A Interest and other financial charges – net Other (4) Foreign currency forward contracts $ 3 $ 1 $ — $ — $ — Effects of cash flow hedges 3 1 — — — Cross-currency swaps — — — 7 — Foreign currency forward and options contracts — — — 4 — Effects of net investment hedges (1) — — — 11 — Interest rate swaps (2) — — — 76 — Debt basis adjustment on Long-term borrowings — — — (84) — Effects of fair value hedges — — — (7) — Foreign currency forward contracts 28 7 — — — Other derivatives (3) — — 2 — 5 Effects of derivatives not designated as hedging instruments 28 7 2 — 5 For the three months ended September 30, 2023 Cost of products Cost of services SG&A Interest and other financial charges – net Other (4) Foreign currency forward contracts $ (5) $ (1) $ — $ — $ — Effects of cash flow hedges (5) (1) — — — Cross-currency swaps — — — 8 — Foreign currency forward and option contracts — — — 1 1 Effects of net investment hedges (1) — — — 9 1 Interest rate swaps — — — — — Debt basis adjustment on Long-term borrowings — — — — — Effects of fair value hedges — — — — — Foreign currency forward contracts (38) (9) — — 4 Other derivatives (3) — — (2) — 10 Effects of derivatives not designated as hedging instruments (38) (9) (2) — 14 For the nine months ended September 30, 2024 Cost of products Cost of services SG&A Interest and other financial charges – net Other (4) Foreign currency forward contracts $ 3 $ 1 $ — $ — $ — Effects of cash flow hedges 3 1 — — — Cross-currency swaps — — — 24 — Foreign currency forward and options contracts — — — 8 — Effects of net investment hedges (1) — — — 32 — Interest rate swaps (2) — — — 11 — Debt basis adjustment on Long-term borrowings — — — (31) — Effects of fair value hedges — — — (21) — Foreign currency forward contracts 21 5 — — — Other derivatives (3) — — 7 — 28 Effects of derivatives not designated as hedging instruments 21 5 7 — 28 For the nine months ended September 30, 2023 Cost of products Cost of services SG&A Interest and other financial charges – net Other (4) Foreign currency forward contracts $ 18 $ 4 $ — $ — $ — Effects of cash flow hedges 18 4 — — — Cross-currency swaps — — — 25 — Foreign currency forward and option contracts — — — 1 1 Effects of net investment hedges (1) — — — 26 1 Interest rate swaps — — — — — Debt basis adjustment on Long-term borrowings — — — — — Effects of fair value hedges — — — — — Foreign currency forward contracts (28) (6) — — 10 Other derivatives (3) — — 5 — 36 Effects of derivatives not designated as hedging instruments (28) (6) 5 — 46 (1) Changes in fair value related to components other than the spot rate are excluded from effectiveness testing for the three and nine months ended September 30, 2024 and 2023. (2) Amount includes $(7) million and $(21) million of interest expense on interest rate derivatives for the three and nine months ended September 30, 2024, respectively. (3) Other derivatives are primarily comprised of embedded derivatives and derivatives related to equity contracts. (4) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Condensed Consolidated Statements of Income.
Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI	The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges. Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Cash flow hedges $ (43) $ 24 $ (13) $ 14 Net investment hedges (1) (116) 64 (57) (7) (1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis. Fair Value of Assets and Liabilities Measured on a Recurring Basis As of September 30, 2024 As of December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Money market funds $ — $ 231 $ — $ 231 $ — $ 200 $ — $ 200 Investment securities 26 — — 26 31 — — 31 Derivatives — 168 — 168 — 128 — 128 Liabilities: Derivatives — 257 — 257 — 269 — 269 Contingent consideration — — 35 35 — — 44 44

COMMITMENTS, GUARANTEES, PROD_2

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranties	An analysis of changes in the liability for product warranties follows. For the nine months ended September 30 2024 2023 Balance at beginning of period $ 192 $ 193 Current-year provisions 143 158 Expenditures (166) (159) Other changes (1) (3) Balance at end of period $ 168 $ 189

RESTRUCTURING ACTIVITIES (Table

RESTRUCTURING ACTIVITIES (Tables)	9 Months Ended
RESTRUCTURING ACTIVITIES (Tables)	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Activities	Net expenses for restructuring initiatives committed to by management through September 30, 2024 are included in the table below. Restructuring Activities For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Employee termination costs $ 19 $ 1 $ 61 $ 26 Facility and other exit costs 2 1 15 2 Asset write-downs 1 1 14 6 Total restructuring activities – net $ 22 $ 3 $ 90 $ 34

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
EARNINGS PER SHARE (Tables)	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Earnings per Share	Earnings Per Share For the three months ended September 30 For the nine months ended September 30 (In millions, except per share amounts) 2024 2023 2024 2023 Numerator: Net income from continuing operations $ 490 $ 386 $ 1,312 $ 1,202 Net (income) loss attributable to noncontrolling interests (19) (7) (40) (33) Net income from continuing operations attributable to GE HealthCare 470 379 1,272 1,169 Deemed preferred stock dividend of redeemable noncontrolling interest — — — (183) Net income from continuing operations attributable to GE HealthCare common stockholders 470 379 1,272 986 Income (loss) from discontinued operations, net of taxes — (4) — (4) Net income attributable to GE HealthCare common stockholders $ 470 $ 375 $ 1,272 $ 982 Denominator: Basic weighted-average shares outstanding 457 455 456 455 Dilutive effect of common stock equivalents 2 3 2 3 Diluted weighted-average shares outstanding 459 458 459 458 Basic Earnings Per Share: Continuing operations $ 1.03 $ 0.83 $ 2.79 $ 2.17 Discontinued operations — (0.01) — (0.01) Attributable to GE HealthCare common stockholders 1.03 0.82 2.79 2.16 Diluted Earnings Per Share: Continuing operations $ 1.02 $ 0.83 $ 2.77 $ 2.16 Discontinued operations — (0.01) — (0.01) Attributable to GE HealthCare common stockholders 1.02 0.82 2.77 2.15 Antidilutive securities (1) 2 4 4 4 (1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SUPPLEMENTAL FINANCIAL INFORM_2

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	9 Months Ended
SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Cash and Cash Equivalents	Cash, Cash Equivalents, and Restricted Cash As of September 30, 2024 December 31, 2023 Cash and cash equivalents (1) $ 3,550 $ 2,494 Short-term restricted cash 18 10 Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position 3,568 2,504 Long-term restricted cash (2) 4 2 Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows $ 3,572 $ 2,506 (1) The increase in cash and cash equivalents was primarily due to proceeds from the issuance of senior unsecured notes by the Company in the third quarter of 2024. Refer to Note 8, “Borrowings” for further information. (2) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.
Schedule of Restricted Cash and Cash Equivalents	Cash, Cash Equivalents, and Restricted Cash As of September 30, 2024 December 31, 2023 Cash and cash equivalents (1) $ 3,550 $ 2,494 Short-term restricted cash 18 10 Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position 3,568 2,504 Long-term restricted cash (2) 4 2 Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows $ 3,572 $ 2,506 (1) The increase in cash and cash equivalents was primarily due to proceeds from the issuance of senior unsecured notes by the Company in the third quarter of 2024. Refer to Note 8, “Borrowings” for further information. (2) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.
Schedule of Inventory	Inventories As of September 30, 2024 December 31, 2023 Raw materials $ 992 $ 961 Work in process 100 91 Finished goods 1,032 908 Inventories (1) $ 2,124 $ 1,960
Summary of Property, Plant and Equipment	Property, Plant, and Equipment – Net As of September 30, 2024 December 31, 2023 Original cost $ 5,356 $ 5,208 Accumulated depreciation (3,176) (3,064) Right-of-use operating lease assets, net of amortization 359 356 Property, plant, and equipment – net $ 2,539 $ 2,500
Schedule of Other Current Assets	All Other Current and Non-Current Assets As of September 30, 2024 December 31, 2023 Prepaid expenses and deferred costs $ 197 $ 147 Financing receivables – net 94 97 Derivative instruments 114 84 Other (1) 72 61 All other current assets $ 476 $ 389 Prepaid pension asset $ 797 $ 716 Equity method and other investments 361 357 Financing receivables – net 178 178 Long-term receivables – net 167 124 Inventories 151 147 Contract and other deferred assets 189 168 Other (2) 255 191 All other non-current assets $ 2,098 $ 1,881 (1) Current Other primarily consists of tax receivables. (2) Non-current Other primarily consists of derivative instruments, indemnity assets associated with separation agreements with GE, capitalized costs associated with cloud computing arrangements, and tax receivables.
Schedule of Other Noncurrent Assets	All Other Current and Non-Current Assets As of September 30, 2024 December 31, 2023 Prepaid expenses and deferred costs $ 197 $ 147 Financing receivables – net 94 97 Derivative instruments 114 84 Other (1) 72 61 All other current assets $ 476 $ 389 Prepaid pension asset $ 797 $ 716 Equity method and other investments 361 357 Financing receivables – net 178 178 Long-term receivables – net 167 124 Inventories 151 147 Contract and other deferred assets 189 168 Other (2) 255 191 All other non-current assets $ 2,098 $ 1,881 (1) Current Other primarily consists of tax receivables. (2) Non-current Other primarily consists of derivative instruments, indemnity assets associated with separation agreements with GE, capitalized costs associated with cloud computing arrangements, and tax receivables.
Schedule of Other Current Liabilities	All Other Current and Non-Current Liabilities As of September 30, 2024 December 31, 2023 Sales allowances and related liabilities $ 215 $ 228 Income and indirect tax liabilities including uncertain tax positions 160 260 Product warranties 168 192 Accrued freight and utilities 127 132 Operating lease liabilities 114 110 Derivative instruments (1) 84 128 Interest payable on borrowings 164 87 Environmental and asset retirement obligations 19 21 Other (2) 356 335 All other current liabilities $ 1,409 $ 1,493 Contract liabilities $ 704 $ 705 Operating lease liabilities 263 273 Environmental and asset retirement obligations 306 265 Income and indirect tax liabilities including uncertain tax positions 205 208 Derivative instruments 183 136 Finance lease obligations 43 38 Sales allowances and related liabilities 23 27 Other (3) 195 225 All other non-current liabilities $ 1,920 $ 1,877 (1) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information. (2) Current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and dividends payable to stockholders. (3) Non-current Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities.
Schedule of Other Noncurrent Liabilities	All Other Current and Non-Current Liabilities As of September 30, 2024 December 31, 2023 Sales allowances and related liabilities $ 215 $ 228 Income and indirect tax liabilities including uncertain tax positions 160 260 Product warranties 168 192 Accrued freight and utilities 127 132 Operating lease liabilities 114 110 Derivative instruments (1) 84 128 Interest payable on borrowings 164 87 Environmental and asset retirement obligations 19 21 Other (2) 356 335 All other current liabilities $ 1,409 $ 1,493 Contract liabilities $ 704 $ 705 Operating lease liabilities 263 273 Environmental and asset retirement obligations 306 265 Income and indirect tax liabilities including uncertain tax positions 205 208 Derivative instruments 183 136 Finance lease obligations 43 38 Sales allowances and related liabilities 23 27 Other (3) 195 225 All other non-current liabilities $ 1,920 $ 1,877 (1) Derivative instruments include the related accrued interest. Refer to Note 12, “Financial Instruments and Fair Value Measurements” for further information. (2) Current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and dividends payable to stockholders. (3) Non-current Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities.
Schedule of Redeemable Noncontrolling Interest	The activity attributable to redeemable noncontrolling interests for the nine months ended September 30, 2024 and 2023 is presented below. Redeemable Noncontrolling Interests For the nine months ended September 30 2024 2023 Balance at beginning of period $ 165 $ 230 Net income attributable to redeemable noncontrolling interests 35 28 Redemption value adjustments (1) — 183 Distributions to and exercise of redeemable noncontrolling interests and other (2) (23) (280) Balance at end of period $ 177 $ 161 (1) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. As a result, these redeemable noncontrolling interests were remeasured to their current redemption value. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to Retained earnings in the Condensed Consolidated Statements of Financial Position. (2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $211 million was paid in the second quarter of 2023.
Schedule of Other Income (Expense)	Other Income (Expense) – Net For the three months ended September 30 For the nine months ended September 30 2024 2023 2024 2023 Net financing income and investment income (loss) $ 5 $ 6 $ (11) $ 19 Equity method income (loss) 2 — 5 9 Change in fair value of assumed obligations (9) (5) (26) (24) Other items, net (1) 11 62 33 81 Total other income (expense) – net $ 9 $ 63 $ 1 $ 85 (1) Other items, net primarily consists of government grants, lease income, gains and losses related to derivatives, and licensing and royalty income for the three and nine months ended September 30, 2024, and change in tax indemnity, gains and losses related to derivatives, licensing and royalty income, and lease income for the three and nine months ended September 30, 2023.

ORGANIZATION AND BASIS OF PRE_3

ORGANIZATION AND BASIS OF PRESENTATION (Details) $ / shares in Units, $ in Millions			3 Months Ended	9 Months Ended
	Jan. 03, 2023 USD ($) shares	Dec. 31, 2022 $ / shares shares	Sep. 30, 2024 segment	Sep. 30, 2023 USD ($)
Subsidiary, Sale of Stock [Line Items]
Sale of stock, percent of stock distributed	80.10%
Sale of stock, number of shares issued \| shares	454,000,000	100
Sale of stock, price per share (in dollars per share) \| $ / shares		$ 1
Net transfers from GE, including Spin-Off-related adjustments \| $	$ 2,840			$ 2,840
Number of reportable segments \| segment			4
GE \| GE HealthCare Technologies Inc
Subsidiary, Sale of Stock [Line Items]
Ownership percentage			2.90%

REVENUE RECOGNITION - Summary o

REVENUE RECOGNITION - Summary of Contract and Other Deferred Assets (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Contract assets	$ 685	$ 600
Other deferred assets	361	400
Contract and other deferred assets	1,046	1,000
Non-current contract assets	93	72
Non-current other deferred assets	96	96
Total contract and other deferred assets	$ 1,235	$ 1,168

REVENUE RECOGNITION - Narrative

REVENUE RECOGNITION - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	$ 2,619		$ 2,623
Contract liabilities	704		$ 705
Contract liabilities, revenue recognized	1,381	$ 1,357
Remaining performance obligation, amount	14,563
Product
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 4,808
Product \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	98%
Remaining performance obligation, period	2 years
Service
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 9,756
Service \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01 \| Period one
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	64%
Remaining performance obligation, period	2 years
Service \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01 \| Period two
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	91%
Remaining performance obligation, period	5 years

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	3 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Sep. 30, 2024 segment
Segment Reporting Information [Line Items]
Number of reportable segments	4
AVS
Segment Reporting Information [Line Items]
Number of subsegments	2

SEGMENT INFORMATION - Schedule

SEGMENT INFORMATION - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Total revenues	$ 4,863	$ 4,822	$ 14,353	$ 14,346
EBIT	795	744	2,217	2,119
Restructuring costs	(22)	(3)	(90)	(34)
Acquisition and disposition-related benefits (charges)	4	14	7	15
Gain (loss) on business and asset dispositions	(1)	0	0	0
Spin-Off and separation costs	(56)	(45)	(182)	(175)
Amortization of acquisition-related intangible assets	(34)	(32)	(100)	(95)
Investment revaluation gain (loss)	(1)	2	(26)	1
Interest and other financial charges – net	(130)	(138)	(383)	(411)
Non-operating benefit income (costs)	102	94	306	332
Income from continuing operations before income taxes	658	636	1,747	1,752
Operating segments \| Imaging
Segment Reporting Information [Line Items]
Total revenues	2,229	2,236	6,462	6,552
EBIT	287	243	660	566
Operating segments \| AVS
Segment Reporting Information [Line Items]
Total revenues	1,216	1,214	3,692	3,712
EBIT	232	254	744	798
Operating segments \| AVS \| Procedural Guidance
Segment Reporting Information [Line Items]
Total revenues	647	641	1,967	1,938
Operating segments \| AVS \| Specialized Ultrasound
Segment Reporting Information [Line Items]
Total revenues	569	573	1,725	1,774
Operating segments \| PCS
Segment Reporting Information [Line Items]
Total revenues	779	764	2,298	2,315
EBIT	82	80	241	273
Operating segments \| PCS \| Monitoring Solutions
Segment Reporting Information [Line Items]
Total revenues	556	573	1,621	1,688
Operating segments \| PCS \| Life Support Solutions
Segment Reporting Information [Line Items]
Total revenues	223	191	677	627
Operating segments \| PDx
Segment Reporting Information [Line Items]
Total revenues	625	589	1,862	1,715
EBIT	193	166	571	473
Other
Segment Reporting Information [Line Items]
Total revenues	15	19	39	52
EBIT	$ 1	$ 1	$ 2	$ 9

RECEIVABLES - Current Receivabl

RECEIVABLES - Current Receivables (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses	$ (104)	$ (98)
Chargebacks	135	144
Nonrelated party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current customer receivables	3,265	3,339
Non-income based tax receivables	139	166
Other sundry receivables	119	118
Current sundry receivables	257	284
Allowance for credit losses	(104)	(98)
Total current receivables – net	$ 3,418	$ 3,525

RECEIVABLES - Long-Term Receiva

RECEIVABLES - Long-Term Receivables (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Receivables [Abstract]
Long-term customer receivables	$ 72	$ 55
Non-income based tax receivables	23	26
Other sundry receivables	102	73
Long-term sundry receivables	125	99
Allowance for credit losses	(30)	(30)
Total long-term receivables – net	$ 167	$ 124

FINANCING RECEIVABLES - Schedul

FINANCING RECEIVABLES - Schedule of Financing Receivable (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses, current	$ (3)	$ (3)
Current financing receivables, net	94	97
Allowance for credit losses, noncurrent	(5)	(5)
Non-current financing receivables, net	178	178
Loans receivable, at amortized cost
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	23	29
Non-current financing receivables, gross	32	37
Investment in financing leases, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	74	71
Non-current financing receivables, gross	$ 151	$ 146

FINANCING RECEIVABLES - Narrati

FINANCING RECEIVABLES - Narrative (Details)	Sep. 30, 2024	Dec. 31, 2023
Financing Receivable, Past Due [Line Items]
Financing receivable, nonaccrual, percent past due	4%	6%
Over 30 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	4%	5%
Over 90 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	4%	5%

LEASES (Details)

LEASES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
LEASES (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Leases [Abstract]
Operating lease liability	$ 378		$ 378		$ 383
Operating lease cost	$ 70	$ 54	$ 189	$ 167

ACQUISITIONS, GOODWILL, AND O_3

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions			3 Months Ended		9 Months Ended
	Apr. 01, 2024	Feb. 17, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Business Acquisition [Line Items]
Consideration transferred, net of cash acquired					$ 259	$ 147
Goodwill			$ 13,138		13,138		$ 12,936
Goodwill reallocation					0
Amortization of acquisition-related intangible assets			77	$ 89	237	$ 278
Imaging
Business Acquisition [Line Items]
Goodwill			3,598		3,598		4,431
Goodwill reallocation					(1,031)
AVS
Business Acquisition [Line Items]
Goodwill			$ 4,967		4,967		$ 3,933
Goodwill reallocation					$ 1,031
MIM Software
Business Acquisition [Line Items]
Percent of interest acquired	100%
Consideration transferred, net of cash acquired	$ 259
Goodwill	195
Deferred tax liabilities	19
Other net assets	7
MIM Software \| Customer-related intangible assets
Business Acquisition [Line Items]
Intangible assets	52
MIM Software \| Developed technology intangible assets
Business Acquisition [Line Items]
Intangible assets	48
MIM Software \| Purchase price
Business Acquisition [Line Items]
Contingent consideration	13
MIM Software \| Service requirements
Business Acquisition [Line Items]
Contingent consideration	$ 23
Caption Health
Business Acquisition [Line Items]
Percent of interest acquired		100%
Consideration transferred, net of cash acquired		$ 127
Contingent consideration		13
Goodwill		94
Intangible assets		60
Deferred tax liabilities		3
Consideration transferred, holdback payment		$ 10

ACQUISITIONS, GOODWILL, AND O_4

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 12,936
Reallocation	0
Acquisitions	195
Foreign currency exchange and other	6
Ending balance	13,138
Imaging
Goodwill [Roll Forward]
Beginning balance	4,431
Reallocation	(1,031)
Acquisitions	195
Foreign currency exchange and other	2
Ending balance	3,598
AVS
Goodwill [Roll Forward]
Beginning balance	3,933
Reallocation	1,031
Acquisitions	0
Foreign currency exchange and other	3
Ending balance	4,967
PCS
Goodwill [Roll Forward]
Beginning balance	2,038
Reallocation	0
Acquisitions	0
Foreign currency exchange and other	1
Ending balance	2,039
PDx
Goodwill [Roll Forward]
Beginning balance	2,534
Reallocation	0
Acquisitions	0
Foreign currency exchange and other	0
Ending balance	$ 2,534

BORROWINGS - Narrative (Details

BORROWINGS - Narrative (Details)	3 Months Ended	9 Months Ended	12 Months Ended
BORROWINGS - Narrative (Details)	Mar. 31, 2024 USD ($)	Sep. 30, 2024 USD ($) series	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Principal debt issued		$ 10,292,000,000	$ 9,452,000,000
Guarantor obligations, maximum exposure			114,000,000
Guarantee obligation, carrying value		3,000,000	4,000,000
Commercial contracts
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		801,000,000	751,000,000
Equipment residual value obligation
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		28,000,000	39,000,000
Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Line of credit outstanding		0	0
Senior unsecured notes \| Senior notes
Debt Instrument [Line Items]
Debt, principal amount		$ 9,250,000,000
Number of debt series \| series		7
Debt repayments		$ 0
4.800% senior notes due August 14, 2029 \| Senior notes
Debt Instrument [Line Items]
Debt, principal amount		$ 1,000,000,000
Stated interest rate		4.80%
Principal debt issued		$ 1,000,000,000	$ 0
5-Year Revolving Credit Facility \| Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Debt, term		5 years	5 years
Maximum borrowing capacity		$ 2,500,000,000
364-Day Revolving Credit Facility \| Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Debt, term		364 days	364 days
Maximum borrowing capacity		$ 1,000,000,000
Floating rate Term Loan Facility due January 2, 2026 \| Line of credit
Debt Instrument [Line Items]
Principal debt issued		$ 1,000,000,000	$ 1,150,000,000
Debt repayments	$ 150,000,000
Floating rate Term Loan Facility due January 2, 2026 \| Line of credit \| Unsecured debt
Debt Instrument [Line Items]
Debt, term		3 years
Maximum borrowing capacity		$ 2,000,000,000

BORROWINGS - Schedule of Long-T

BORROWINGS - Schedule of Long-Term Borrowings (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Principal debt issued	$ 10,292	$ 9,452
Less: Unamortized debt issuance costs and discounts	36	35
Add: Cumulative basis adjustment for fair value hedges	57	25
Total borrowings	10,312	9,442
Less: Short-term borrowings	1,007	1,006
Long-term borrowings	9,306	8,436
Long-term borrowings, current	$ 1,004	1,002
Senior notes \| 5.550% senior notes due November 15, 2024
Debt Instrument [Line Items]
Stated interest rate	5.55%
Principal debt issued	$ 1,000	1,000
Senior notes \| 5.600% senior notes due November 15, 2025
Debt Instrument [Line Items]
Stated interest rate	5.60%
Principal debt issued	$ 1,500	1,500
Senior notes \| 5.650% senior notes due November 15, 2027
Debt Instrument [Line Items]
Stated interest rate	5.65%
Principal debt issued	$ 1,750	1,750
Senior notes \| 4.800% senior notes due August 14, 2029
Debt Instrument [Line Items]
Stated interest rate	4.80%
Principal debt issued	$ 1,000	0
Senior notes \| 5.857% senior notes due March 15, 2030
Debt Instrument [Line Items]
Stated interest rate	5.857%
Principal debt issued	$ 1,250	1,250
Senior notes \| 5.905% senior notes due November 22, 2032
Debt Instrument [Line Items]
Stated interest rate	5.905%
Principal debt issued	$ 1,750	1,750
Senior notes \| 6.377% senior notes due November 22, 2052
Debt Instrument [Line Items]
Stated interest rate	6.377%
Principal debt issued	$ 1,000	1,000
Line of credit \| Floating rate Term Loan Facility due January 2, 2026
Debt Instrument [Line Items]
Principal debt issued	1,000	1,150
Other
Debt Instrument [Line Items]
Principal debt issued	$ 42	$ 52

POSTRETIREMENT BENEFIT PLANS -

POSTRETIREMENT BENEFIT PLANS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Plan asset or obligation reporting threshold			$ 50
Defined benefit plan, expected future employer contributions, next fiscal year	$ 336		336
Defined contribution plan, employer contribution amount	27	$ 28	100	$ 94
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Curtailment loss		17
OPEB Plans
Defined Benefit Plan Disclosure [Line Items]
Curtailment loss	0	0	0	0
Defined benefit plan, employer contribution amount			99
GE HealthCare Supplemental Pension Plan \| Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, employer contribution amount			91
Other Pension Plans \| Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Curtailment loss	$ 0	$ 0	0	$ 0
Defined benefit plan, employer contribution amount			$ 67

POSTRETIREMENT BENEFIT PLANS _2

POSTRETIREMENT BENEFIT PLANS - Components of Expense (Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Non-operating	$ (102)	$ (94)	$ (306)	$ (332)
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Curtailment loss (gain)		17
Pension Plans \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	7	8	21	25
Interest cost	227	237	681	715
Expected return on plan assets	(284)	(292)	(851)	(878)
Amortization of net loss (gain)	(19)	(30)	(57)	(96)
Amortization of prior service cost (credit)	2	1	6	2
Curtailment loss (gain)	0	17	0	17
Non-operating	(74)	(67)	(221)	(240)
Net periodic expense (income)	(67)	(58)	(200)	(215)
Pension Plans \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	6	6	18	18
Interest cost	50	53	150	157
Expected return on plan assets	(64)	(65)	(190)	(192)
Amortization of net loss (gain)	5	2	15	7
Amortization of prior service cost (credit)	0	(1)	0	(3)
Curtailment loss (gain)	0	0	0	0
Non-operating	(9)	(11)	(25)	(31)
Net periodic expense (income)	(3)	(5)	(7)	(13)
OPEB Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	2	2	6	6
Interest cost	14	15	41	45
Expected return on plan assets	0	0	0	0
Amortization of net loss (gain)	(15)	(16)	(45)	(48)
Amortization of prior service cost (credit)	(22)	(22)	(66)	(66)
Curtailment loss (gain)	0	0	0	0
Non-operating	(23)	(23)	(70)	(69)
Net periodic expense (income)	$ (21)	$ (21)	$ (64)	$ (63)

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	25.50%	39.30%	24.90%	31.40%
Deferred tax provision, tax matters agreement		$ 105		$ 105
Income tax benefit, change in tax indemnities		$ 30		$ 30
Deferred tax liabilities, undistributed foreign earnings					$ 30

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	$ 7,817	$ 7,114	$ 7,145	$ 9,362
Other comprehensive income (loss) before reclassifications – net of taxes	114	(339)	33	(264)
Reclassifications from AOCI – net of taxes	(41)	(46)	(114)	(173)
Other comprehensive income (loss)	74	(385)	(80)	(437)
Spin-Off related adjustments – net of taxes				2,000
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	(35)	0	(35)
Equity, ending balance	8,335	7,142	8,335	7,142
Accumulated other comprehensive income (loss) – net
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(845)	70	(691)	(1,878)
Equity, ending balance	(771)	(280)	(771)	(280)
Currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(1,812)	(1,757)	(1,706)	(1,845)
Other comprehensive income (loss) before reclassifications – net of taxes	177	(143)	70	(84)
Reclassifications from AOCI – net of taxes	0	0	0	0
Other comprehensive income (loss)	177	(143)	70	(84)
Spin-Off related adjustments – net of taxes				28
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	(35)	0	(36)
Equity, ending balance	(1,635)	(1,865)	(1,635)	(1,865)
Other comprehensive income (loss) before reclass, tax	27	(16)	13	1
Reclass from AOCI, tax	0	0	0	0
Spin-Off related adjustments, tax				0
Pension and Other Postretirement Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	961	1,847	1,033	(42)
Other comprehensive income (loss) before reclassifications – net of taxes	(29)	(214)	(27)	(190)
Reclassifications from AOCI – net of taxes	(38)	(50)	(111)	(156)
Other comprehensive income (loss)	(67)	(264)	(138)	(346)
Spin-Off related adjustments – net of taxes				1,972
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	0	0	1
Equity, ending balance	894	1,583	894	1,583
Other comprehensive income (loss) before reclass, tax	8	69	7	60
Reclass from AOCI, tax	12	16	33	49
Spin-Off related adjustments, tax				(509)
Cash flow hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	6	(20)	(18)	9
Other comprehensive income (loss) before reclassifications – net of taxes	(34)	18	(10)	10
Reclassifications from AOCI – net of taxes	(3)	4	(3)	(17)
Other comprehensive income (loss)	(36)	22	(12)	(7)
Spin-Off related adjustments – net of taxes				0
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	0	0	0
Equity, ending balance	(30)	2	(30)	2
Other comprehensive income (loss) before reclass, tax	10	(6)	3	(4)
Reclass from AOCI, tax	$ 1	$ (1)	$ 1	5
Spin-Off related adjustments, tax				$ 0

FINANCIAL INSTRUMENTS AND FAI_3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Derivative [Line Items]
Cash flow hedge loss to be reclassified within 12 months	$ 35
Derivative, potential effect of rights of offset to assets and liabilities	85	$ 41
Cash, cash equivalents, and restricted cash	3,568	2,504
Cross-currency swaps \| Net investment hedges \| Designated as hedging instrument
Derivative [Line Items]
Payment for settlement of hedge	94
Money market funds \| Recurring
Derivative [Line Items]
Cash, cash equivalents, and restricted cash	231	200
Other cash equivalents \| Recurring
Derivative [Line Items]
Cash, cash equivalents, and restricted cash	2,303	1,023
Estimated fair value
Derivative [Line Items]
Borrowings	10,937	9,959
Carrying value
Derivative [Line Items]
Borrowings	$ 10,312	$ 9,442

FINANCIAL INSTRUMENTS AND FAI_4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Fair Values (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Derivative [Line Items]
Gross Notional	$ 11,229	$ 9,591
Fair Value – Assets	168	128
Fair Value – Liabilities	257	269
Designated as hedging instrument \| Cash flow hedges
Derivative [Line Items]
Gross Notional	1,504	1,356
Fair Value – Assets	2	8
Fair Value – Liabilities	42	30
Designated as hedging instrument \| Cash flow hedges \| Foreign currency forward contracts
Derivative [Line Items]
Gross Notional	1,504	1,356
Fair Value – Assets	2	8
Fair Value – Liabilities	42	30
Designated as hedging instrument \| Net investment hedges
Derivative [Line Items]
Gross Notional	3,773	3,200
Fair Value – Assets	35	9
Fair Value – Liabilities	195	215
Designated as hedging instrument \| Net investment hedges \| Cross-currency swaps
Derivative [Line Items]
Gross Notional	2,148	2,209
Fair Value – Assets	18	0
Fair Value – Liabilities	174	204
Designated as hedging instrument \| Net investment hedges \| Foreign currency forward and options contracts
Derivative [Line Items]
Gross Notional	1,625	991
Fair Value – Assets	17	9
Fair Value – Liabilities	20	11
Designated as hedging instrument \| Fair value hedges
Derivative [Line Items]
Gross Notional	1,700	1,000
Fair Value – Assets	61	35
Fair Value – Liabilities	5	10
Designated as hedging instrument \| Fair value hedges \| Interest rate swaps
Derivative [Line Items]
Gross Notional	1,700	1,000
Fair Value – Assets	61	35
Fair Value – Liabilities	5	10
Not designated as hedging instrument
Derivative [Line Items]
Gross Notional	4,251	4,035
Fair Value – Assets	70	76
Fair Value – Liabilities	16	14
Not designated as hedging instrument \| Foreign currency forward contracts
Derivative [Line Items]
Gross Notional	3,854	3,597
Fair Value – Assets	33	19
Fair Value – Liabilities	13	12
Not designated as hedging instrument \| Other derivatives
Derivative [Line Items]
Gross Notional	397	438
Fair Value – Assets	37	57
Fair Value – Liabilities	$ 3	$ 2

FINANCIAL INSTRUMENTS AND FAI_5

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Cumulative Basis Adjustment for Fair value Hedges (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Long-term borrowings designated in fair value hedges	$ 1,753	$ 1,023
Hedged Liability, Statement of Financial Position [Extensible Enumeration]	Long-term borrowings	Long-term borrowings
Cumulative basis adjustment included in the carrying amount	$ 57	$ 25

FINANCIAL INSTRUMENTS AND FAI_6

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Cash flow hedges	$ (43)	$ 24	$ (13)	$ 14
Net investment hedges	$ (116)	$ 64	$ (57)	$ (7)

FINANCIAL INSTRUMENTS AND FAI_7

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Effect of Derivatives Instruments on Statements of Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	$ 0	$ 0	$ 0	$ 0
Effects of net investment hedges	0	0	0	0
Effects of fair value hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	2	(2)	7	5
SG&A \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	0	0	0	0
SG&A \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
SG&A \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
SG&A \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0	0
SG&A \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0	0
SG&A \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	2	(2)	7	5
Interest and other financial charges – net
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of net investment hedges	11	9	32	26
Effects of fair value hedges	(7)	0	(21)	0
Effects of derivatives not designated as hedging instruments	0	0	0	0
Interest and other financial charges – net \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	0	0	0	0
Interest and other financial charges – net \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	7	8	24	25
Interest and other financial charges – net \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	4	1	8	1
Interest and other financial charges – net \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	76	0	11	0
Interest and other financial charges – net \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	(84)	0	(31)	0
Interest and other financial charges – net \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	0	0	0	0
Other
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of net investment hedges	0	1	0	1
Effects of fair value hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	5	14	28	46
Other \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	0	4	0	10
Other \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
Other \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	1	0	1
Other \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0	0
Other \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0	0
Other \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	5	10	28	36
Interest expense \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	(7)		(21)
Product \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	3	(5)	3	18
Effects of net investment hedges	0	0	0	0
Effects of fair value hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	28	(38)	21	(28)
Product \| Cost of revenue \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	3	(5)	3	18
Effects of derivatives not designated as hedging instruments	28	(38)	21	(28)
Product \| Cost of revenue \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
Product \| Cost of revenue \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
Product \| Cost of revenue \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0	0
Product \| Cost of revenue \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0	0
Product \| Cost of revenue \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	0	0	0	0
Service \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	1	(1)	1	4
Effects of net investment hedges	0	0	0	0
Effects of fair value hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	7	(9)	5	(6)
Service \| Cost of revenue \| Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	1	(1)	1	4
Effects of derivatives not designated as hedging instruments	7	(9)	5	(6)
Service \| Cost of revenue \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
Service \| Cost of revenue \| Foreign currency forward and options contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
Service \| Cost of revenue \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0	0
Service \| Cost of revenue \| Debt basis adjustment on Long-term borrowings
Derivative Instruments, Gain (Loss) [Line Items]
Effects of fair value hedges	0	0	0	0
Service \| Cost of revenue \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	$ 0	$ 0	$ 0	$ 0

FINANCIAL INSTRUMENTS AND FAI_8

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Assets:
Money market funds	$ 3,568	$ 2,504
Recurring
Assets:
Investment securities	26	31
Derivatives	168	128
Liabilities:
Derivatives	257	269
Contingent consideration	35	44
Recurring \| Money market funds
Assets:
Money market funds	231	200
Level 1 \| Recurring
Assets:
Investment securities	26	31
Derivatives	0	0
Liabilities:
Derivatives	0	0
Contingent consideration	0	0
Level 1 \| Recurring \| Money market funds
Assets:
Money market funds	0	0
Level 2 \| Recurring
Assets:
Investment securities	0	0
Derivatives	168	128
Liabilities:
Derivatives	257	269
Contingent consideration	0	0
Level 2 \| Recurring \| Money market funds
Assets:
Money market funds	231	200
Level 3 \| Recurring
Assets:
Investment securities	0	0
Derivatives	0	0
Liabilities:
Derivatives	0	0
Contingent consideration	35	44
Level 3 \| Recurring \| Money market funds
Assets:
Money market funds	$ 0	$ 0

COMMITMENTS, GUARANTEES, PROD_3

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Narrative (Details) $ in Millions	Dec. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Guarantor obligations, maximum exposure	$ 114

COMMITMENTS, GUARANTEES, PROD_4

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Schedule of Product Warranties (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of period	$ 192	$ 193
Current-year provisions	143	158
Expenditures	(166)	(159)
Other changes	(1)	(3)
Balance at end of period	$ 168	$ 189

RESTRUCTURING ACTIVITIES - Sche

RESTRUCTURING ACTIVITIES - Schedule of Restructuring Activities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 19	$ 1	$ 61	$ 26
Facility and other exit costs	2	1	15	2
Asset write-downs	1	1	14	6
Total restructuring activities – net	$ 22	$ 3	$ 90	$ 34

RESTRUCTURING ACTIVITIES - Narr

RESTRUCTURING ACTIVITIES - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Expected restructuring expense remaining	$ 21
Restructuring liabilities	$ 80	$ 68

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator:
Net income from continuing operations	$ 490	$ 386	$ 1,312	$ 1,202
Net (income) loss attributable to noncontrolling interests	(19)	(7)	(40)	(33)
Net income from continuing operations attributable to GE HealthCare	470	379	1,272	1,169
Deemed preferred stock dividend of redeemable noncontrolling interest	0	0	0	(183)
Net income from continuing operations attributable to GE HealthCare common stockholders	470	379	1,272	986
Income (loss) from discontinued operations, net of taxes	0	(4)	0	(4)
Net income attributable to GE HealthCare common stockholders	$ 470	$ 375	$ 1,272	$ 982
Denominator:
Basic weighted-average shares outstanding	457	455	456	455
Dilutive effect of common stock equivalents (in shares)	2	3	2	3
Diluted weighted-average shares outstanding	459	458	459	458
Basic Earnings Per Share:
Continuing operations (in dollars per share)	$ 1.03	$ 0.83	$ 2.79	$ 2.17
Discontinued operations (in dollars per share)	0	(0.01)	0	(0.01)
Attributable to GE HealthCare common stockholders (in dollars per share)	1.03	0.82	2.79	2.16
Diluted Earnings Per Share:
Continuing operations (in dollars per share)	1.02	0.83	2.77	2.16
Discontinued operations (in dollars per share)	0	(0.01)	0	(0.01)
Attributable to GE HealthCare common stockholders (in dollars per share)	$ 1.02	$ 0.82	$ 2.77	$ 2.15
Antidilutive securities (in shares)	2	4	4	4

SUPPLEMENTAL FINANCIAL INFORM_3

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 3,550	$ 2,494
Short-term restricted cash	18	10
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position	3,568	2,504
Long-term restricted cash	4	2
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows	$ 3,572	$ 2,506	$ 2,420	$ 1,451

SUPPLEMENTAL FINANCIAL INFORM_4

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 992	$ 961
Work in process	100	91
Finished goods	1,032	908
Inventories	$ 2,124	$ 1,960

SUPPLEMENTAL FINANCIAL INFORM_5

SUPPLEMENTAL FINANCIAL INFORMATION - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Original cost	$ 5,356	$ 5,208
Accumulated depreciation	(3,176)	(3,064)
Right-of-use operating lease assets, net of amortization	359	356
Property, plant, and equipment – net	$ 2,539	$ 2,500

SUPPLEMENTAL FINANCIAL INFORM_6

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current and Noncurrent Assets (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses and deferred costs	$ 197	$ 147
Financing receivables – net	94	97
Derivative instruments	114	84
Other	72	61
All other current assets	476	389
Prepaid pension asset	797	716
Equity method and other investments	361	357
Financing receivables – net	178	178
Long-term receivables – net	167	124
Inventories	151	147
Contract and other deferred assets	189	168
Other	255	191
All other non-current assets	$ 2,098	$ 1,881

SUPPLEMENTAL FINANCIAL INFORM_7

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current and Noncurrent Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Sales allowances and related liabilities	$ 215	$ 228
Income and indirect tax liabilities including uncertain tax positions	160	260
Product warranties	168	192
Accrued freight and utilities	127	132
Operating lease liabilities	114	110
Derivative instruments	84	128
Interest payable on borrowings	164	87
Environmental and asset retirement obligations	19	21
Other	356	335
Contract liabilities	704	705
Operating lease liabilities	263	273
Environmental and asset retirement obligations	306	265
Income and indirect tax liabilities including uncertain tax positions	205	208
Derivative instruments	183	136
Finance lease obligations	$ 43	$ 38
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	All other non-current liabilities	All other non-current liabilities
Sales allowances and related liabilities	$ 23	$ 27
Other	195	225
All other non-current liabilities	1,920	1,877
Nonrelated party
Related Party Transaction [Line Items]
All other current liabilities	$ 1,409	$ 1,493

SUPPLEMENTAL FINANCIAL INFORM_8

SUPPLEMENTAL FINANCIAL INFORMATION - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Supplier Finance Program [Line Items]
Supplier finance program obligation	$ 403	$ 365
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable
Minimum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	30 days
Maximum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	180 days

SUPPLEMENTAL FINANCIAL INFORM_9

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period		$ 165	$ 230
Net income attributable to redeemable noncontrolling interests		35	28
Redemption value adjustments		0	183
Distributions to and exercise of redeemable noncontrolling interests and other		(23)	(280)
Balance at end of period		177	161
Redemption of noncontrolling interests	$ 211	$ 0	$ 211

SUPPLEMENTAL FINANCIAL INFOR_10

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Other Income (Expense) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net financing income and investment income (loss)	$ 5	$ 6	$ (11)	$ 19
Equity method income (loss)	2	0	5	9
Change in fair value of assumed obligations	(9)	(5)	(26)	(24)
Other items, net	11	62	33	81
Total other income (expense) – net	$ 9	$ 63	$ 1	$ 85

RELATED PARTIES AND TRANSITIO_2

RELATED PARTIES AND TRANSITION SERVICES AGREEMENT (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
All other non-current assets	$ 2,098		$ 2,098		$ 1,881
All other non-current liabilities	1,920		1,920		1,877
Related party
Related Party Transaction [Line Items]
All other non-current assets	70		70		81
All other non-current liabilities	41		41		$ 33
TSA \| Related party
Related Party Transaction [Line Items]
Transaction amount	$ 40	$ 94	$ 138	$ 286